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ABSTRACT 
Malaria is a life-threatening parasitic disease transmitted by Anopheles mosquitoes. 
Today approximately 40% of the world's population is at risk of malaria. It causes 
more than 300 million acute illnesses and up to 2.7 million deaths annually. Malaria is 
especially dangerous to pregnant women and children. Plasmodium falciparum is the 
most common and the most deadly type of malaria infection. The incidence is 
increasing in many tropical underdeveloped countries because of resistance of the 
parasite to common drugs and insecticide resistance. Research nowadays focuses on 
the development of a malaria vaccine to count-act the disease. 
The Plasmodium falciparum Merozoite Surface Protein-142 (MSP-142) is a blood-
stage malaria candidate vaccine. Recombinant Bombyx mori nuclear polyhedrosis 
virus (BmNPV) which carries the MSP-142 cDNA was constructed to infect silkworm 
(Bombyx mori) larvae for the production of recombinant MSP-142 (BVp42). 
Characterization of this malaria vaccine candidate showed that it can mimic the 
antigenic and immunogenic property of native MSPl. However, attempts purify it by 
conventional methods were unsuccessful. In order to facilitate downstream process, 
MSP-142 was expressed in silkworm as histidine-tagged, secreted polypeptides. Two 
recombinant BmNPV constructs, each carrying either a C- or N-terminal hexa-
histidine tag of the PfMSP-Ui gene, have been constructed. The recombinant 
BmNPV were separately used to infect BmNPV cell culture (in vitro) and silkworms 
(in vivo) to express the corresponding recombinant hexa-histidine tagged PfMSP-142 
recombinant proteins. 
In the present study, three kinds of protein were purified by MAC. By using 
monoclonal antibody, Mab 5.2 and anti-MSP-hs polyserum, the results suggested that 
the major protein was our target protein and the other two co-purified contaminants 
ii 
were the aggregation and degradation fragment of the target protein. The 
recombinant proteins also appear to have a disulphide-dependent conformation in the 
EGF-Iike domains similar to the native PfMSP-1 by Competitive ELISA. Both of the 
recombinant proteins expressed in the present study can elicit a high antibody 
response by immunization. All the results lead to a conclusion that both of the 
recombinant proteins are suitable to be further developed as malaria vaccine. Further, 
experiments are needed to show their effectiveness in inhibiting parasite proliferation 
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Background of Malaria 
CHAPTER 1 
BACKGROUND OF MALARTA 
1.1 Epidemiology 
Malaria is caused by protozoan parasites of the genus Plasmodium. Four species of 
Plasmodium can produce the disease in its various forms: Plasmodium falciparum 
Plasmodium vivax, Plasmodium ovale and Plasmodium malaria. Plasmodium 
falciparum is the most widespread and dangerous of the four species. It can lead to 
fatal cerebral malaria when untreated. 
Malaria is an internationally devastating disease, producing nearly 600 million new 
infections and 3 million deaths each year. This disease affects all age groups. But in 
endemic areas, the greatest suffering is bome by children less than five years old and 
pregnant women. Around 800 thousand children under the age of five die from 
malaria every year, making this disease one of the major causes of infant and 
juvenile mortality. Malaria during pregnancy can cause miscarriages, foetal death, 
low birth weight and premature delivery. 
Malaria occurs in over 100 countries and territories. More than 40% of the people in 
the world are at risk. Large areas of Central and South America, Hispaniola (Haiti 
and the Dominican Republic), Africa, the Indian subcontinent, Southeast Asian the 
Middle East, and Oceania are considered malaria-risk areas. (Figure 1) 
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Figure I: World distribution of malaria (Adopted from WHO) 
Malaria Endemic Countries, 2003 
Countries with Malaria Risk ? \pU V 
Note： This map shows oountries with endemic malaria. , > 
VC In most of these countires, malaria risk is limited to certain areas. 
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1.2 Mode of Infection 
Malaria is a multi-stage parasite which is spread through the female Anopheles 
mosquito vector. When a carrier female mosquito takes a blood meal, malaria 
sporozoites are released into the bloodstream from the mosquito's salivary glands. 
From the bloodstream, the sporozoites enter the liver parenchymal cells and invade 
the hepatocyes. It is estimated that a sporozoite clears the blood circulation in less 
than 60 minutes. Inside the hepatocytes, the sporozoites undergo asexual 
amplification, called exoerythrocytic schizogony. In 1-2 weeks, a single sporozoite 
can give rise to 30 thousand merozoites. During this pre-erythrocytic stage, no illness 
is induced by malaria. (Figure 2) 
1.2.1 The asexual erythrocytic stage 
The liver schizont bursts, releasing the merozoites into the bloodstream where the 
beginning of the erythrocytic phase begins. The merozoites are extracellular for only 
1-2 minutes before they rapidly invade erythrocytes (Figure 3). In the erythrocyte the 
merozoite goes through the ring, the trophozoite, and the schizont stages (Figure 4). 
Again, asexual amplification occurs with as many as 36 merozoites being produced 
within one erythrocyte. When the erythrocytic schizont ruptures (Figure 5), the 
merozoites spill into the blood once again; it is during this phase that malaria-
associated morbidity and mortality occur. The merozoites continue in a repeated 
cycle of infecting erythrocytes, multiplying, and bursting the erythrocytes. 
3 
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Figure 2: Life cycle of the malaria parasite. (Adopted from: http://www-
micro.msb.le.ac.uk/224/Bradley/Biology.htmI) 
The life-cycle of Plasmodium nivax in man & 
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Figure 3 
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1.2.2 The sexual transmission stage 
During this repeated cycle, some merozoites differentiate into male and female 
gametocytes. It is in this form that they can be taken up by the mosquito vector 
during a blood meal. Inside the mid-gut of the mosquito, fertilization occurs, 
producing zygotes, which develop into ookinetes. The ookinetes form oocysts, which 
then grow and divide and rupture to give rise to sporozoites, which then migrate to 
the salivary glands. At this stage, the infectious cycle of malaria repeats itself again 
(Figure 2). 
1.2.3 Clinical features 
The symptoms of uncomplicated malaria can be rather non-specific and the diagnosis 
can be missed if doctors are not alert to the possibility of this disease. Untreated 
malaria can progress to severe forms that may be rapidly (<24 hours) fatal. The most 
frequent symptoms include fever and chills, which can be accompanied by headache, 
myalgias, arthralgias, weakness, vomiting, and diarrhea. 
1.2.3.1 Severe malaria 
Patients with sever malaria have coma, jaundice, renal failure, hypoglycemia, 
acidosis, severe anemia, high parasite count, and hyperpyrexia. Severe malaria is 
ideally treated in an intensive care or high dependency unit where patients can be 
monitored closely both clinically and biochemically. 
1.2.3.2 Cerebral malaria 
Cerebral malaria collectively involves the clinical manifestations of Plasmodium 
falciparum malaria that induce changes in mental status and coma. Clinical 
manifestations of cerebral malaria are numerous, but there are three primary 
6 
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symptoms generally common to both adults and children: (1) impaired consciousness 
with non-specific fever, (2) generalized convulsions and neurological sequelae; and 
(3) coma that persists for 24-72 hours, initially reusable and then unrousable. The 
mortality rate is between 25-50%. If a person is not treated, it is fatal in 24-72 hours. 
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1.3 Conventional Control and Vaccination 
1.3.1 Prevention of infection 
The main method in removing adult mosquitoes in our household habitat is to spray 
insecticide. The insecticide most widely used has been DDT. However there have 
been studies demonstrating that DDT contamination in human breast milk may cause 
neurological abnormalities in babies. DDT has been replaced by organophosphate or 
carbonate insecticides such as malathion where DDT resistance has been detected. 
However, these compounds are considerably more expensive. Insecticide-treated 
bednets have been touted as a safe and inexpensive strategy to prevent malaria 
infection. 
1.3.2 Treatment once infected 
Modem management of severe malaria consists of rapid administration of an 
appropriate antimalarial drugs and measures to avoid complications such as anemia, 
convulsions, or hypoglycemia. Antimalarials are very effective but may have side 
effects, such as abdominal pain, nausea, vomiting, headache, dizziness, blurred 
vision, and itching. Resistance to many antimalarial drugs is becoming increasingly 
common. For example, chloroquine, a drug once very effective, is now being 
questioned as the first-line of defense drug in countries such as Africa, where malaria 
is endemic in numerous areas. 
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1.3.3 Drug resistance 
A major factor attributing to the increase in resistance of the parasites to previously 
effective drugs is the migration of non-immune populations from malaria free areas 
to endemic zones. People who are non-immune are at high risk. Since population 
movements and intensive urbanization may lead to inadequate development of 
sanitation and health care. The over use of drugs for treatment of malaria tends to 
increase the drug resistance of the parasites. In recent years, single- and multiple-
drug resistant strains of Plasmodium falciparum have been widespread (Figure 6); 
this makes the control of malaria by chemotherapy much more difficult (the Medical 
Letter, Inc., 1998; World Health Organization, 1999). Resistance of malaria parasites 
to antimalarial can be attributed to mutations of the enzymes that are targets of such 
drugs, notably the dihydrofolate reductase (Hyde, 1990; Nzila-Mounda et al, 1998) 
and dihydropteroate synthetase (Wang et al, 1997). 
Furthermore, decreased level of drug accumulation (Krogstad et al, 1987; Bray, 
Howells & Ward，1992), amplification and over-expression of drug resistance-related 
gene pfmdrl (Wilson et al., 1989; Foote et a!.，1990; Cowman, Galatis & Thompson, 
1994) seriously affect the efficiency of antimalarial drugs. Other unknown 
mechanisms may also be involved in drug resistance development. As conventional 
antimalarial strategies have lost their effectiveness, vaccine development appears to 
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1.3.4 Vaccine strategies 
Due to the increase of malaria cases and drug resistance in many parts of the world, 
adequate treatment of the malaria is becoming increasingly difficult and effective 
controls are urgently needed. Development of a vaccine towards malaria seems to be 
an urgent agenda. The development of a malaria vaccine is one strategy that could 
prove to be the most cost-effective means in controlling both the transmission of 
infection and the impact of the disease. Despite the fact that considerable effort has 
been invested in vaccine research for decades, no effective malaria vaccine is 
available at the moment. Nevertheless, better understanding of the mechanisms of 
immunity to malaria and advances in biomedical technology are increasing the 
feasibility of producing an effective vaccine. 
Even though natural infection of malaria does not produce complete immunity 
towards the parasite, long-term exposure to malaria has been shown to induce partial 
protective immune response to malaria. In the partially immune subject (Table 1) 
there is fewer and less dense parasitemias, a reduction in malaria-related illness, 
significant protection from death, and antibody production towards erythrocytic stage 
parasites. An effective vaccine will probably need to incorporate multiple 
components that will induce an immune response towards the different stages of the 
malaria infection. An ideal malaria vaccine should be safe, cheap, easy to 
manufacture, easy to administer and confer life-long immunity. 
11 
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Table 1 Possible Immune Response from Natural Infection 
Life Cycle stage Immune Reponse 
• Abs that block hepatocyte invasion 
Sporozoite 
• Abs that kill the sporozoite via complement fixation or opsonization 
• CTL mediated lysis 
• CD4+ help for the activation and differentiation of CTL 
Infected Hepatocyte 
• Localized cytokine release by T cells or APCs 
• ADCC or C’ mediated lysis 
"“ • Localized cytokine release that directly kills infected erythrocyte or 
intracellular parasites 
• Abs that agglutinate the merozoites before schizont rupture 
• Abs that block merozoite invasion ofRBCs 
• Abs that kill iRBC via opsonization of phagocytotic mechanisms 
Asexual Erythrocytic 
• Abs engulfed with the merozoite at time of invasion which kill 
intraerythrocytic parasite 
• Abs which agglutinate iRBCs and prevent cytoadherence by 
blocking 
receptor-ligand interactions 
• Abs which neutralize harmful soluble parasite toxins 
• Cytokines which kill gametocytes within the iRBC 丨' 
• Abs that kill gametocytes within iRBC via C 
Sexual Erythrocytic • Abs that interfere with fertilization 
• Abs that inhibit transformation of the zygote into the ookinete 
• Abs that block the egress of the ookinete from the mosquito midgut 
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1.3.5 Vaccine Candidate 
Since the asexual blood stage is responsible for the clinical expression of the disease, 
a vaccine targeting this stage would reduce morbidity and mortality by eliminating or 
reducing the parasite load. In developing the vaccine, the aim would be to induce 
blocking antibody towards the circulating merozoites, preventing them from 
infecting red blood cells. 
Since the clinical symptoms of malaria only manifest during the blood stage invasion, 
a vaccine against this stage would prevent or reduce the severity and complications 
of the disease. Perhaps, even eliminate malaria. In red blood cells, the parasites 
appear to be well positioned to avoid host response as it lack class I and II MHC 
molecules and the antigen-processing machinery. Hences, direct T cell-mediated 
responses are not induced to determinants presented at the host cell surface. 
Only during schizont rupture is the parasite directly exposed to the immune system. 
For a very brief period, daughter merozoites have to attach to and enter new red 
blood cells. Much attention has therefore been given to parasite molecules that 
interact with the host cells during RBC invasion as potential targets of host immune 
response. A number of proteins have been identified on the merozoite surface as 
targets of the immune system. These molecules include the merozoite surface protein 
(MSP), apical merozoite surface antigen 1 (AMA-1), and erythrocyte binding antigen 
(EBA). 
From previous studies, they have shown that mice immunized with native and 
recombinant merozoite surface protein were protected from the lethal challenge of 
the parasite (Chang et al., 1989; Ling, Ogun & Holder，1994). This protection 
appears to be antibody mediated as a monoclonal antibody on passive immunization 
13 
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is effective against blood stage challenge infection (Spencer Valero et a/.’ 1998; 
Freeman, Trejdosiewicz & Cross，1980). In a non-human primate model, Actus 
monkeys immunized with the merozoite of human malaria Plasmodium falciparum 
were completely protected against a lethal challenge of the homologous erythrocytic 
malaria parasites (Siddiqui, 1977). Moreover, as the major merozoite surface proteins 
were showed to elicit antibody response from human (Table 1) during a natural 
Plasmodium falciparum infection (Gentz et al., 1988)，they are of particular interest 
as potential anti-malaria vaccine candidates. 
14 
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1.4 Vaccine Candidate PyMSP-142 
1.4.1 PyMSP-1 
The merozoite surface proteins are synthesized during schizogony (Figure 7) as 
precursor polypetptides that vary in size and amino acid sequence. Eight 
P.falciparum MSPs have been identified and designated MSPl to 8. Merozoite 
surface proteins are potential malaria vaccine candidates as they play important roles 
in the initial recognition and attachment of merozoites to the RBC surface. As 
proteins on the merozoite surface are exposed to the host immune system, they are 
thought to be targets of immune responses. Antibodies against MSP neutralize the 
parasite by agglutinating or opsonizing merozoites, preventing RBC recognition and 
invasion, or affecting growth of the new intracellular parasite within the RBC 
(Holder, Guevara & Uthaipibull et cd., 1999). 
Merozoite surface protein 1(MSP-1) is a glycoprotein synthesized as a high 
molecular weight (�185-205 kDa) precursor protein (McBride & Heidrich，1987; 
Lyon, Geller, Haynes, Chulay & Weber, 1986; Holder, Sandhu & Hillman et al, 
1987). The protein precursor is processed at least twice by protease enzymes into a 
number of fragments. During schizont rupture, primary processing occurs, giving rise 
to major fragments of approximately 82 (MSP -I82) , 28-30 (MSP -I30) , 38 (MSP-hs) 
and 42 (MSP - I42) kDa. These proteins form a non-covalently associated complex 
held together on the surface of the merozoite by the 42kDa fragment ((McBride & 
Heidrich, 1987; Lyon, Geller, Haynes, Chulay & Weber，1986; Holder, Sandhu & 
Hillman et a/•，1987). At the time of merozoite invasion, secondary processing, 
which is a prerequiaite for RBC invasion, takes place (Blackman & Holder, 1992). 
The calcium-dependent proteolytic processing cleaves the C-terminal membrane-
15 
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bound 42kDa fragment into two products (Blackman & Holder，1992). The soluble 
33kDa fragment (MSP-133) corresponding to the N-terminal region of MSP-142 is 
shed from the free merozoite surface (Blackman, Whittle & Holder, 1991). The 
membrane-bound 19kDa carboxyl-terminal fragment (MSP-119), which contains two 
epidermal growth factor (EGF)-like domains (Blackman, Ling, Nicholls & Holder， 
1991) is the only fragment carried by the invading merozoite into the RBC 
(Blackman, Heidrich, Donachie, McBride & Holder，1990) (Figure 8). 
MSP-1 is anchored onto the merozoite surface via a glycosylphosphatidylinositol 
(GPI) membrane anchor (Haldar, Ferguson & Cross，1985; McConville & Ferguson, 
1993). MSP-1 exists primarily in two allelic forms in the asexual erythrocytic 
haploid stage only one of the two allelic forms (PNG-MAD20 and Wellcome type) 
will be present. Since, MSP-1 is polymorphic, intragenic recombination has been 
suggested to be the mechanism to generate new MSP-1 alleles in the progeny (Kerr, 
Ranford-Cartwright & Walliker, 1994). MSP-1 protein can be divided into 17 blocks 
of sequences with different degrees of sequence variation (Tanabe et a/” 1987) 
(Figure 9). A short segment of amino acids composed of the tripeptide repeats is 
located at the amino terminal region of MSP-1. Distinct from the amino terminal part, 
the carboxyl terminal 19kDa fragment (block 17) of MSP-119 is highly conserved 
(Jongwutiwes, Tanabe & Kanbara^ 1993; Kang & Long, 1995). On the basis of 
amino acid sequence similarity, two EGF-like motifs are present on MSP-119 and 
they are highly conserved among different species of malaria (Blackman et al, 1991) 
(Figure 10). In these motifs, six cysteine residues form three disulphide bonds that 
are responsible for the formation of the EGF-like domain (Figure 11) (Chitarra et a!., 
1999; Morgan et al., 1999) 
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Figure 8: Schematic showing processing merozotie surface protein 1 (MSP-1) 
(modified from Backman et al.,). Panel (A) shows primary processing, and (B) 
shows secondary processing. 
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Background of Malaria 
Figure 11. Comparison of the Stereo view of MSPl Domains. The first domain of 
MSPl is shown in green and the second domain in purple. The two images are 
superimposed to show homelogy. Cystine residues are shown in yellow. (Chitarra, V. 
etal 1999) 
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1.4.2 PyMSP-l42 
Among the various anti-malaria vaccine candidates, MSP-1 is the most studied one 
and it is targeted at the anti-erythrocytic stage. The whole molecule of MSP-1 has 
been shown to induce protection against lethal P. falciparum challenge in mice and 
monkeys (Holder & Freeman^ 1981; Siddiqui, Tarn & Kramer et al, 1987). 
Antibodies specific for MSP-1 from malaria-immune donors form immune 
complexes with the parasite and inhibit merozoite dispersal (Lyon et a/.，1997). 
Subsequent studies have shown that regions of MSP-1 are responsible for protection 
include MSP-138 (Nikodem & Davidson，2000)，MSP-119, MSP - I42 and also N-
terminal region of MSP-182 (Tian et aL, 1997). 
Congenic mice with different genetic backgrounds are capable of producing P/MSP-
1 specific antibodies by immunization with PfMSP-1 protein, indicating that the 
immune response was not MHC haplotype-restricted (Chang et al, 1989). In 
subsequent rodent experiments, it has been shown that mice immunized with 
recombinant Plasmodium yoelii MSP-119 are protected against an infection challenge 
(Daly & Long，1993). This protection appears to be antibody mediated (Ling et al., 
1997) as monoclonal antibodies generated from mice have been demonstrated to 
react with the C-terminal cysteine region of P. yoelii MSP-1. Certain Mab against 
Plasmodium falciparum MSP-119 that inhibit erythrocytic invasion in vitro also 
possess the ability to inhibit the secondary processing of PyMSP-Ui (Blackman et al, 
1994). This secondary process involves proteolytic cleavage ofMSP-Ui into 33kDa 
and 19kDa fragments and only the latter peptide would remain on the merozoite 
surface after entry into RBC (Figure SB). In addition, transfusion of specific 
antibody against MSP-1 to recipient has been shown to be effective in protection of 
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animals challenged with blood stage parasite (Majarian et al., 1984; Spencer Valero 
et al, 1998). In non-human primate, the first successful immunization of 
experimental monkey against a human malaria parasite was reported in 1977 
(Siddiqui, 1977). Later, P>1SP-1 immunization was further confirmed to be 
effective in protecting monkeys against a lethal malaria parasite challenge (Hall et al., 
1984; Siddiqui et a!., 1986; Siddique et al, 1987). Moreover, sera from these 
pyMSP-1 immunized monkeys and rabbits could strongly inhibit parasitic growth in 
vitro (Hui & Siddiqui，1987). Most importantly, immunological cross-reactivity was 
observed from /yMSP-1 proteins isolated from two different strains of malaria and 
this was believed to be due to the recognition of the conserved determinants. Thus, a 
MSP-1 based vaccine may be effective against blood stage infection from an array of 
parasite isolates (Hui, Hashimoto & Chang，1992). 
Subsequent findings showed that anti-P>ISP-l antibodies were mainly reactive 
towards the carboxyl-terminal processing fragment P>lSP-l42, and more specifically, 
the P>ISP.li9 fragment (Hui et a!.’ 1996; Ling, Ogun & Holder, 1994). A 
recombinant FJMSP'Ui was expressed by the baculovirus Autographa Califomica 
Nuclear Polyhedrosis Virus (AcNPV) (denoted AcNPVp42) was shown to be highly 
immunogenic (Hui et a!.’ 1993; Chang et a/.，1992). And anti-BVp42 antisera raised 
from rabbits have shown high cross-reactivity with P/MSP-1 of different isolates of 
Plasmodium falciparum. Moreover, the antisera could completely inhibit parasitic 
growth in vitro. In field studies, human sera collected from malaria endemic area 
could recognize the AcNPVp42 to the extent as PyMSP-1. High antibody titer was 
produced when Aotus monkeys were immunized with BVp42. Their antisera were 
also cross-reacted with P>ISP-1 from different isolates o i P l a s m o d i u m falciparum 
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and were highly inhibitory to parasitic growth (Chang et al., 1996). Most importantly， 
immunized monkeys were protected against the challenge of erythrocytic malaria 
parasites. In addition, the T-lymphocytes of these immunized animals could be 
induced to proliferate significantly by purified PfMSP-1 protein and whole parasites, 
indicating that P^MSP-l-specific T cells were involved in the immunity against the 
erythrocytic malaria parasites and they were effectively primed by AcNPVp42. In 
contrast, the same P/MSP-142 polypeptide, when expressed as a yeast intracellular 
product (denoted Yp42), could not be recognized by the anti-iyMSP-1 and anti-
AcNPV antisera (Chang et cd., 1992). Moreover, significantly lower anti-Yp42 
antibody titer was obtained when rabbit were immunized with this protein and 
antisera raised showed little cross-reactivity with i^MSP-l and fixed whole parasites. 
It has been suggested that the native disulphide-dependent conformat iona l epitopes 
ofPyMSP-l42, from the two EGF-like domains were poorly expressed in yeast; while 
they were authentically expressed in the baculovirus expression system. The above 
immunological evidence, together with other data (Hui et a/.，1992; 1993; 1996), 
strongly indicates that the two EGF-like domains in MSP - I19 constitute the major 
target of antibody response. Hence, P /MSP - I19 was evaluated as the minimal 
fragment for a PfMSP-1-based vaccine (Kaslow, Hui & Kumar, 1994). Rabbits 
immunized with an active yeast-expressed recombinant PfMSP-119 protein (YMSP-
produced a high antibody titer cross-reacting with P^MSP-l. However, the 
antibodies were found to be ineffective in inhibiting malaria parasites. Moreover, T-
lymphocytes from BVp42-protected Aotus monkeys (Chang et aL, 1996) and from 
immune human donors (Egan et a/.，1997) could not be effectively stimulated to 
proliferate by YMSP-I19. Thus, the relevant T-cell epitopes responsible for induction 
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ofT-cell response was probably absent in the PfMSP-li9 fragment. The use of this 
minimal fragment as an anti-malarial vaccine is therefore not favorable. 
It has been shown that native protein conformation is essential for antigenicity, 
immunogenicity and induction of growth-inhibitory antibodies (Locher & Tam^ 
1993). Bacterial expressed PfMSP-1 protein and its processing fragment (Holder, 
Freeman & NichoUs, 1988; Herrera et a/.，1990; Etlinger et a!.’ 1991) and PfMSP-1 
synthetic peptides (Patarroyo et aL, 1987) have been shown to be less effective in 
inducing immunity and protection to malaria. The reason for this maybe due to the 
lack of proper secondary and tertiary structure required for the induction of 
protective immunity. For example in E.coli, the formation of disulphide bond critical 
for native conformation in the highly conserved EGF-like domain was probably not 
possible (Bialy etai, 1987). 
From the above studies, it can be concluded that for producing a vaccine base on 
iyMSP-1，the main consideration is to recreate the important conformational epitopes 
that can mimic the immunogenicity and protective efficacy of the native protein. 
Among the common protein expression systems available, the baculovims 
expression system certainly has distinct advantages over others in this respect. 
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1.5 Cloning and Expression oiP/MSV-Uj 
The baculovirus expression system has come to be accepted as one the most efficient 
methods for production of many recombinant proteins. The system is based on the 
insect nuclear polyhedrosis viruses (NPV), a group of large rod-shaped DNA viruses, 
into which the gene or genes of interest are cloned. The recombinant virus can then 
be used to infect insect cells in culture, with subsequent expression of the 
recombinant proteins. 
1.5.1 Characteristics of Baculoviruses 
Baculoviruses are a diversified group of closed-circular double-stranded DNA 
viruses of the family Baculoviridae, which are found mostly in insects. The haculo 
portion of the name refers to the rod-shaped capsids of the virus particles (O'Reilly 
et al, 1994). Baculoviridae can be divided into two sub-families, the 
Euhaculovirmae (occluded baculoviruses) and the Nudibaculovirinae (non-occluded 
baculoviruses). The Euhaculovirmae produces crystalline proteinaceous structures 
called occlusion bodies, which are absent in the Nudibaculovirinae (Vialard, Arif & 
Richardson, 1995). The Eubaculovirinae subfamily is made up of two genera; 
granulosis viruses (GVs) and nuclear polyhedrosis viruses (NPVs). The virus used in 
this study is the Bombyx mori Nuclear Polyhedrosis Virus (BmNPV). Most 
baculoviruses isolated are very host-specific, and the majority of Euhaculovirmae 
have been isolated from larvae of the Lepidoptera family (for example, moths and 
butterflies). Baculovirus vectors commonly used in recombinant protein expression 
include the Autographa califomica Nucleaar Polyhedrosis Virus (AcNPV) and 
BmNPV. 
25 
Background of Malaria 
1.5.2 Infection cycle of Baculoviruses 
The occlusion bodies containing mature virus particles are taken up by a susceptible 
larval host as food contaminants. The alkaline environment of the larval midget 
dissolves the occlusion bodies and releases the virus particles. Primary infection of 
the midgut epithelial cells occurs through a receptor-mediated membrane fusion 
process. The nucleocapsids are targeted to the nucleus where replication and 
transcription of the viral DNA occur. Budding viruses from the initially infected cells 
cause secondary infection to adjacent cells through a receptor-mediated adsorptive 
endocytosis mechanism. At a late stage of the infection process, the mature virus 
particles are multiply packed into occlusion bodies which comprised mainly of a 
protein called polyhedrin. Finally, the infected larva dies and disintegrates. The 
occluded viruses, which are protected by the occlusion bodies, are dispersed from the 
dead bodies and consumed by another susceptible larva, thereby reinitiating a new 
infection cycle (Figure 12). 
1.5.3 Control of viral gene expression in virus-infected cells 
Baculovims gene expression is regulated in a cascade-like fashion. This temporal 
regulation allows the grouping of baculovims genes into three phases during 
infection: early (E), late (L), and very late (VL). Although most baculovims genes 
can be placed into one of the above classes, some may be transcribed in more than 
one phase. The E genes are transcribed prior to viral DNA replication and generally 
encode proteins with regulatory functions (e.g. EGT and HEL). Whereas the L and 
VL genes are activated during or after replication. The L genes are activated before 
the VL genes and maximally transcribed between 12 and 24 hours post-infection. 
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This group of genes encodes structural proteins of the budding virus and occlusion-
derived virus (e.g. P39 and GP41). The VL genes, which are under the control of a 
strong promoter, are hyper-expressed following the activation of the L genes and 
remain active from 48 hours post-infection onward. VL proteins are those involved 
in the processes of occlusion and cell lysis; e.g. polyhedrin and plO (Figure 13). 
1.5.4 Merits of Baculovinis Expression System 
Baculovinis expression system has been successfully employed to express 
biologically active recombinant proteins for agricultural and pharmaceutical use. 
Examples include humun a-interferon (Maeda “ a/•，1985), human granulocyte-
macrophage colony-stimulating factor (Shi et al, 1996) and grass carp growth 
hormone (Hoe/a/. , 1998). 
There are a number of advantages in using baculovinis as an expression vector 
(Maeda, 1989, 1994). First, being eukaryotic origin, insect cells can carry out many 
of the post-translational modifications of higher eukaryotes, including acylation, 
acetylation, a-amidation, and phosphorylation. In addition, proteins with appropriate 
signal sequences may be secreted, and glycosylated at the correct sites. Second, the 
double-standed DNA genome of the virus can be easily manipulated by general 
molecular biology techniques and the rod-shaped viral capsid is rather “flexible m 
accommodating large DNA insert. In this regard, the polyhedrin gene {polh) is the 
best choice because it is non-essential for viral reproduction and is driven by a 
powerful promoter. Besides, the occlusion-negative trait is a good marker to indicate 
the successful insertion of a foreign gene under the control oipolh promoter. Third’ 
an additional benefit in replacing or deleting the polyhedrin gene is that 
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baculoviruses that are occlusion negative are more sensitive to inactivation. It 
effectively makes the virus unable to survive outside the laboratory, an advantage in 
terms of environmental safety. The system is intrinsically safe to animal, being 
unable to replicate in species other than a limited range of insects. 
Because of the advantages mentioned, baculovims expression system seems to be an 
ideal system for the expression of the P^MSP-Ui protein. 
1.5.5 Bombyx mod Nuclear Polyhedrosis Virus (BmNPV) 
The BmN cell line was originally derived from the pupal ovarian tissues of silkworm 
Bombyx mori. Wild-type (wt) BmNPV (T3 isolate) was a virus cell line; the virus 
was propagated and amplified by in vitro infection of BmN cells. The large size of 
the BmNPV genomic DNA (~130kbp) makes it sensitive to minor mechanical 
damage such as shearing during pipetting. Because of this, direct insertion of DNA 
into the viral genome by conventional cloning strategy is not possible. In order to 
insert the DNA into BmNPV, an indirect cloning method was employed. In this 
study, a BmNPV-based transfer vector, pBM030, was used. Recombinant BmNPVs 
were generated by cotransfecting BmN cells with the purified BmNPV genomic 
DNA and the recombinant transfer vector. By homologous recombination, the target 
DNA sequence could be inserted into the viral genome. 
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1.6 Aims of study 
AcNPV has been successfully used to produce a recombinant AcNPVp42 protein for 
vaccination of animals against erythrocytic malaria (Chang et aL, 1992). Our 
laboratory has also developed an efficient BmNPV expression system by infecting 
silkworm larva. The BmNPV produced recombinant BVp42 was confirmed to be 
biologically and immunologically active as that produced by the AcNPV system. The 
BmNPV (silkworm system) has an advantage over AcNPV (cell culture system) to 
produce a large quantity of recombinant protein with lower cost. However, the 
recombinant protein produced in the silkworm hemolymph was difficult to be 
purified using conventional chromatography. It could only be efficiently purified by 
immunoaffinity chromatography using monoclonal antibody, mAb5.2. In the 
preparation of materials for human clinical trial, proteins purified by immunoaffinity 
chromatography require stringent demonstration of safety as required by agencies 
such as the Food and Drug Administration (FDA) of USA. For instance, if using 
murine monoclonal antibodies (Mab5.2), the affinity column must be free of 
contaminants such as DNA and viruses, and the purified protein products must be 
free of immunoglobulins that may leach from the column. To avoid the regulatory 
issues of using immunoaffini ty chromatography, we explored and evaluated if 
immobilized metal affinity chromatography could be used to purify a his-tag 
recombinant P>ISP-l42 protein. 
In this thesis, the purification processes, and characterization of the recombinant his-
tagged PfMSP-l42 proteins are described. 
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CHAPTER 2 
MATFRTAT.S AND METHODS 
2.1 Materials 
2 . 1 . 1 Reagents for M S P - I 4 2 in vivo expression 
2.1.1.1 DTT solution 
A 250 mM stock solution of dithiothreitol (DTT) was prepared by dissolving 
0 7725g DTT in 20ml O.OIM sodium acetate solution, pH 5.5. The DTT solution was 
sterilized by 0.2\xm pore-size membrane filtration. One-millilitre aliquots were 
prepared and kept at -20�C. 
2.1.1.2 Grace's insect cell culture medium 
It was purchased from GibcoBRL (Grand Island, N. Y.) in liquid form in a package 
size of SOOml/bottle. The medium was supplemented with 500mg/L CaCb, 
2800mg/L KCl, 330mg/L lactalbumin hydrolysate, 3330mg/L yeastolate and L-
glutamine. The medium was stored at 4°C. 
2.1.2 Reagents for IMAC purification 
2.1.2.1 Imidazole 
Imidazole was purchased from USB in pure powder form of IKg/bottle. 
2.1.2.2 Start Buffer 
Start buffer for N-terminal MSP-Ui was prepared by dissolving 2.56g Na^HPOi 
(20mM) and 58.44g NaCl (IM) in a final volume of IL dH^O. The pH is adjusted to 
7.0. The buffer was filtered with 0.45^im filter before use and stored at 4�C. 
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Start buffer for C-terminal MSP-142 was prepared by dissolving 2.56g Na^HPO! 
(20mM) and 116.88g NaCl (2M) in a final volume of IL dH^O. The pH is adjusted 
to 8.0. The buffer was filtered with 0.45|im filter before use and stored at 4°C. 
2.1.2.3 Regeneration Buffer 
It consist of 0.05M EDTA (reagent grade) and 0.5M NaCl in dH.O. 0.45^m filtered 
before use and stored at room temperature. 
2.1.2.4 UF buffer 
62.3g NaBr in 250ml MOCK buffer 
2.1.2.5 DTT 
A 100 mM stock solution of dithiothreitol (DTT) was prepared by dissolving 1.55g 
DTT in 100ml O.OIM sodium acetate solution, pH 5.5. The DTT solution was filtered 
with 0.45^im filter. One-millilitre aliquots were prepared and kept at 一 2 0 ° C . 
lOOmM DTT was diluted 5-fold by PBS before use. 
2.1.2.6 Storage buffer 
It was 20% ethanol (reagent grade) and filtered with 0.45nm filter before use and 
stored at 4°C. 
2.1.3 Reagents for Immuno-affmity (Mab 5.2) purification 
2.1.3.1 Start Buffer 
Start buffer of immuo-affmity (Mab 5.2) purification was prepared by dissolving 
58.44gNaCl (IM) in IL IxPBS. (PBS/lMNaCl) 
PBS was a 5x stock solution prepared by dissolving 40g NaCl, Ig KCl, 7.2g 
Na2HP04 and 1.2g KH2P04 in a final volume of IL. The stock solution was diluted 
5-fold with pH adjusted to 7.0 with HCl before use. 
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The buffers were filtered with 0.45|im filter before use and stored at 4°C. 
2.1.3.2 Washing Buffer 
Washing buffer 1: PBS/lMNaCl 
Washing buffer 2: PBS/IM NaCl with 0.1% NP-40 
The buffers were filtered with 0.45^im filter before use and stored at 4°C. 
2.1.3.3 Elution Buffer 
Elution buffer was prepared by dissolving 3.75g (lOOmM) glycine in a final volume 
of 500ml dHiO and the pH was adjusted to 2.7 with HCl. 
lOOmM Tris buffer was prepared for adjusting the elution to final pH 7.0. Tris buffer 
was dissolving 1.21 Ig Tris-base in a final volume of 100ml dUjO. 
The buffers were filtered with 0.45nm filter before use and stored at 4°C. 
2.1.4 Reagents for SDS-PAGE 
2.1.4.1 Stacking gel and Resolving gel 
Solutions for making gels were prepared according to Sambrook et al (1989). For a 
30% acrylamide mix, a working solution of 29% (w/v) acrylamide plus 1% (w/v) bis 
in ddHiO was prepared. It was filtered through a 0.45|im pore size membrane filter 
before use. The solution was stored at 4°C in a dark bottle. Other reagents were 
prepared by dissolving the corresponding chemicals in ddHiO. 
2.1.4.2 Tris-glycine electrophoresis buffer 
A 5x stock solution was prepared by dissolving 15.1g Tris-base and 94g glycine in 
900ml dH^O. Fifty milliliter (10% (w/v) SDS solution was added, and the volume 
was adjusted to IL with dH^O. The stock solution was diluted 5-fold before use. 
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2.1.4.3 Sample loading buffer 
A 2x working solution was prepared with 4% (w/v) SDS, l25mM Tris-Cl (pH 6.8)’ 
30% (w/v) glycerol and 0.002% (w/v) bromophenol blue. For reducing disulphide 
bonds of proteins, 5-10% (v/v) P-mercaptoethanol (Sigma, St. Louis, MO) was 
added just before use. 
2.1.4.4 SDS-PAGE staining solution 
It was prepared by dissolving 0.25g Coomassie Brilliant Blue R-250 (Sigma, St. 
Louis, MO) in 90ml 1: 1 (v/v) methanol: dHiO mixture and 10ml glacial acetic acid. 
2.1.4.5 SDS-PAGE destaining solution 
It was prepared by mixing 250ml ethanol with 80ml glacial acetic acid and made up 
to IL with dHiO. 
2.1.4.6 Silver stain fixative enhancer solution 
It was prepared according to the instructions of the Silver Stain Plus Kit (Bio-Rad， 
Hercules, CA). It consisted of 10% (v/v) fixative enhancer concentrate (provided by 
the kit), 50% (v/v) reagent grade methanol and 10% (v/v) reagent grade glacial acetic 
acid in dcffibO. 
2.1.4.7 Silver stain staining substrate solution 
It was prepared according to the instructions of the Silver Stain Plus Kit (Bio-Rad, 
Hercules, CA). Just before use, 1.5ml each of the silver complex solution, reduction 
moderator solution, and image development reagent (all provided by the kit) were 
mixed and made up to 25ml with ddH^O (Solution 1). At the same time, 1 4% (w/v) 
development accelerator solution (Solution 2) was also freshly prepared by 
dissolving the development accelerator powder (provided by the kit) in ddH^O. The 
two solutions were mixed together to constitute the staining substrate solution. 
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2.1.5 Reagents for Western Blotting 
2.1.5.1 Bjerrum and Schafer-Nielsen transfer buffer 
It was prepared by dissolving 5.82g Tris and 2.93g glycine in a minimal volume of 
ddHiO. 3.75ml 10% (w/v) SDS solution and 200ml analytical grade absolute 
methanol were then added. The final volume was made up to IL with ddH^O. The 
pH of the buffer ranged from 9.0 to 9.4. 
2.1.5.2 PBS 
A 5X stock solution was prepared by dissolving 40g NaCl, Ig KCl, 7.2g Na2HP04 
and 1.2g KH2P04 in a final volume of IL. The stock solution was diluted 5-fold 
with pH adjusted to 7.0 with HCl before use, 
2.1.5.3 Washing Buffer 
Washing buffer PBST was prepared by added 0.05% (v/v) Tween® 20 (USB, 
Cleveland, OH) inlxPBS. 
2.1.5.4 Blocking solution 
It was PBST with 5% (w/v) non-fat dried milk powder (PBS/0.5%M). 
2.1.5.5 AP substrate buffer 
It was a buffer with 0.IM Tris, O.IM NaCl and 5mM MgCl� . The pH of the buffer 
was adjusted to 9.5 with IM HCl. 
2.1.5.6 AP substrate solution 
Nitro blue tetrazolium (NBT) solution was prepared by dissolving lOmg (if tablet， 
one tablet of NBT [Sigma, St. Louis, MO] was used) in 1ml ddH.O. The solution 
was wrapped in aluminum foil and kept at -20°C. 5.Bromo-4-chloro-3.indolyl 
phosphate (BCIP) solution was prepared by dissolving 50mg BCIP (Sigma, St. Louis, 
MO) in iml dciH.0 and kept at -20«C. Just before use, 300^x1 NBT solution and 30^1 
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BCIP solution were added to 10ml AP substrate buffer (for each 7 x 5 cm2 
membrane) to constitute the AP substrate solution. 
2.1.6 Reagents of ELISA 
2.1.6.1 ELISA coupling buffer 
It was prepared by dissolving 1.6g NazCO� and 2.9g NaHCOs in IL dHjO. The pH 
of the solution was adjusted to 9.6 with IM HCl. 
2.1.6.2 Washing buffer 
Washing buffer for ELISA was PBST. 
2.1.6.3 Blocking buffer 
Blocking buffer for ELISA was PBST with 3% (w/v) non-fat dried milk powder 
(PBST/0.3%M). 
2.1.6.4 Saturation buffer 
It was prepared by dissolving 1% (w/v) bovine serum albumin (BSA; Sigma, St. 
Louis, MO) in Ix PBS pH 7.4 (PBS/BSA). 
2.1.6.5 Secondary antibody buffer 
It was prepared by dissolving 1% (w/v) BSA in PBST (PBST/BSA). 
2.1.6.5 Horseradish peroxidase (HRP) substrate buffer 
It was lOOmM trisodium citrate solution with pH adjusted to 4.1 with IM HCl. 
2.1.6.6 HRP substrate 
A 50x ABTS stock solution was prepared by dissolving 0.499g 2, 2，-azino-bis-(3-
e thy lbenz th iazo l ine -6 - su l fon ic acid) diammonium salt (ABTS; Sigma, St. Louis, MO) 
in 20ml HRP substrate buffer. One-millilitre aliquots were prepared and kept at -
20X. Just before use, one aliquot of ABTS was warmed at 37�C. For each milliliter 
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of substrate solution, 200^1 50x ABTS and 1.4…30% (v/v) H2O2 were made up to 
1ml with HRP substrate buffer. 
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2.2 Methods 
2.2.1 In vivo expression of MSP-I42 
2.2.1.1 Rearing of silkworms 
Silkworms were provided by Dr. Z. Q. Meng of the Zhejiang Academy of 
Agricultural Sciences, Hangzhou. They were cultivated in spacious plastic trays at 
27°C and fed with fresh mulberry leaves (Appendix 1) or artificial diet from 
Hangzhou. 
2.2.1.2 Infection of silkworms with recombinant BmNPV and extraction of 
hemolymph (Choudary et al., 1995) 
Silkworms at early fifth instar (one to three days after molting, body weight between 
2.5 to 4.0g) were used for infection. Larvae were starved for three hours before viral 
infection. At the same time, recombinant BmNPV (prepared by colleague) was 
diluted 10-fold in Grace's insect cell culture medium supplemented with Ix PSF to 
� 1 . 8 X lO^pfu/^il. Silkworms were anesthetized on ice for 20 minutes and then gently 
cleaned with 70% ethanol. Twenty microlitres of the diluted virus was injected 
longitudinally underneath the dorsal cuticle of each larva by a 1/2 c.c. Ultra-Fine® II 
short needle insulin syringe (Becton Dickinson). Infected silkworms were fed as 
usual at room temperature until symptoms of severe viral infection were observed 
(e.g. cessation of food consumption and movement, yellow cuticles, and softened 
body texture). To collect the hemolymph, prolegs of the silkworms were cut with 
scissors and hemolymph was allowed to drain into a sterile 1.5ml eppendorf tube. 
Dithiothreitol (DTT) was immediately added to a final concentration ofS-lOmM to 
prevent melanization. The hemolymph was flash-frozen in liquid nitrogen and then 
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stored at -80�C for recombinant PfMSP-l42 (C-terminal & N-terminal) protein 
purification. 
2.2.2 IMAC purification of N-terminal PfMSP-142 
2.2.2.1 Nickel ion Charged Chelating Sepharose Fast Flow column (IMAC) 
(Pharmacia Biotech) 
Chelating Sepharose Fast Flow gel is supplied in 20% ethanol. 6ml gel was 
transferred to 15ml Falcon tube and it was washed with 2 bed-volumes of dHaO three 
times. Then the gel was charged with nickel ion by adding 0.5 gel volume of O.IM 
NiS04 solution. The charging matrix was incubated at room temperature for 5 
minutes with end-over-end rotation. The charged gel was sedimented by centrifuging 
at l,500rpm for 2 minutes. The supernatant was decanted and the gel was further 
washed with two gel-volumes ofdH20 three times. The charged gel was equilibrated 
by washing with two bed-volumes of Start buffer for three times and stored at 4oC 
until ready for hemolymph binding in IMAC purification. 
2.2.2.2 Purification recombinant N-hisPfMSP-Ui protein by Nickel ion charged 
chelating Sepharose Fast Flow column 
Hemolymph sample was centrifuged at 13,000rpm at for 20 minutes. The 
supernatant containing N-HisPfMSP-l42 protein was collected and stored in aliquots 
of 5ml each. 5ml hemolymph sample was dialyzed with a 3000-8000 NMWL 
dialysis tubing against 5L Start buffer at 4 � C overnight. The dialyzed hemolymph 
sample was diluted 3-fold and filtered with 0.45nm filter, then mixed with 2.5ml 
charged chelating matrix in a 50ml Falcon tube. The mixture was gently shaken until 
fully-resuspended. It was incubated at 4°C overnight with end-over-end rotation. 
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Afterwards, the slurry mixture was packed into a glass Econo-Column (10mm x 
10mm, BioRad). The flow through was reloaded three times in order to recover gel 
adhered to the wall of the Falcon tube. 
The eluent of the final pass was saved as flow through (FT). The column was then 
washed with 20-bed volumes of Start buffer and the first 2 bed-volume of eluent was 
also saved (stwf) for checking any contaminant present later. The washing buffer 
(SOmM imidazole in Start buffer, pH 7.0) was used in second round of washing in a 
total volume 50-bed volumes. In the washing, the last one-bed volume fraction was 
collected (Iwf). Elution of absorbed materials by elution buffer (0.4M imidazole in 
Start buffer, pH 7.0) was carried out in a total of four one-bed volume fractions. All 
the fractions collected were stored at 4°C. The column was regenerated by washing 
with 5-bed volume of regeneration buffer. 
Once the chelating gel was unchanged, it will return from the charged light blue 
colour to the original white gel colour. The column was reconditioned for future used 
by washing with 3-bed volume three times ofdHzO followed by the same volumes of 
20% ethanol (reagent grade). Chelating gel resuspended in 20% ethanol was 
transferred to 15ml Falcon tube and stored at 4oC. In all of the above steps, the 
column was eluted by gravitation flow. 
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2.2.3 IMAC purification of C-terminal PyMSP-l42 
Nickel ion charged Chelating Sepharose Fast Flow was prepared as described in 
section 2.2.2.1. 
Hemolymph sample was centrifuged at 13,000rpm at 4 � C for 20 minutes. The 
supernatant containing C-HisP^MSP-Ui protein was collected and divided into 
aliquots of 5ml each. 
5ml hemolymph sample was diluted by adding 5ml UF buffer, and 5ml 5-fold diluted 
DTT. The diluted sample was ultra-centrifliged at 42,000rpm at 4 � C for 24 hours. 
The bottom 1/3 part (5ml) of the content was collected. This sample was dialyzed 
with a 3000-8000 NMWL dialysis tubing against 5L Start buffer at 4 T for 24 hours 
and changed new buffer for every 8 hours. The dialyzed hemolymph sample was 
diluted 3-fold and filtered with a 0.45|im filter. It was then mixed with 2.5ml charged 
chelating matrix in a 50ml Falcon tube. The mixture was gently shaken until fully-
resuspended and it was then incubated at 4°C overnight with end-over-end rotation. 
Afterwards, the slurry mixture was packed into a glass Econo-Column 
chromatography column (10mm x 10mm, BioRad). The flow through was reloaded 
three times in order to recover the gel adhered to the wall of the Falcon tube. 
The eluent of the final pass was saved as flow through (FT). The column was then 
washed with 20-bed volumes of Start buffer and the first 2 bed-volume of eluent was 
also saved for checking any contaminant present later. In the second round of 
washing, 50-bed volume washing buffer (50mM imidazole in Start buffer, pH 6.0) 
was used. In this washing, the last one-bed volume fraction was saved for analysis. 
Elution of absorbed materials by elution buffer (0.4M imidazole in Start buffer, pH 
5.5) was carried out in a total of four one-bed volume fractions. All the fractions 
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collected were stored at 4°C. The column was regenerated by washing with 5-bed 
volume of regeneration buffer and regenerated for future used as described before. 
2.2.4 Gel filtration purification 
Samples purified from 5ml hemolymph by IMAC was concentrated into 1ml and 
then was loaded onto a Superose 6 column (10cm x 30cm Pharmacia). 
Chromatography was performed in a FPLC system (Pharmacia). The column was 
eluted with a buffer containing 20mM Na2HP04, IM NaCl and pH7.0 at a flow rate 
of 0.5ml per minute. The elution profile was monitored by absorption at 280nm 
( O D 2 8 0 ) 
2.2.5 Ion-exchange purification 
Samples purified from 5ml hemolymph by IMAC were reloaded onto ion-exchange 
column three times. The Start buffer was 20mM Na^HPCU and eluted with increasing 
concentration of NaCl. Different pH was used for different kinds of ion-exchange 
column. 
2.2.6 Immuno-affinity (Mab 5.2) purification 
Samples were dialyzed against 5L PBS/IM NaCl pH7.0 (Start buffer, SB). Then the 
sample was loaded into a 2ml Mab 5.2 immuno-affmity column. Monoclonal 
antibody Mab 5.2 is an IgG2b class antibody, which is specific for a disulphide-
dependent conformational epitope on the carboxyl terminal of native P^MSP-l 
protein. The unabsorbed material (FT) was collected and wash with 5-bed volumes 
ofPBS/ lM NaCl/0.1%NP-40 and 5-bed volumes ofPBS/lM NaCl pH 7.0. Finally, 
the absorbed materials were eluted by washing with four one-bed volumes of elution 
buffer (O.IM glycine, pH2.7). 
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2.2.6 Protein Analysis 
2.2.6.1 Protein s epa ra t ion by sodium dodecylsulphate po lyac ry l amide gel 
electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out according to Laemmli (1970). Resolving and stacking 
gels were prepared and casted in the Mini-PROTEIN® II electrophoresis cell 
(BioRad). Each protein sample was mixed with an equal volume of 2x loading buffer 
and heated at 95�C for five minutes. Samples were then centrifuged at room 
temperature at 13,000rpm for five minutes. The clarified supernatants were loaded 
and the gels were run at SOmA/gel. 
2.2.6.2 Coomassie Brilliant Blue R-250 staining of SDS gels 
Gels were stained in SDS-PAGE staining solution at room temperature overnight 
with gentle shaking. The gels were then destained in destaining solution at 55oC with 
gentle shaking until the background was removed. After rinsing with tap water, the 
gels were dried under vacuum. 
2.2.6.3 Silver staining of SDS gels by Sliver Stain Plus Kit (Bio-Rad, Hercules， 
CA) 
Each piece of resolving gel was fixed in 50ml fixative enhancer solution for 20 
minutes at room temperature with gentle shaking. The gel was then rinsed at room 
temperature for 20 minutes in 100ml ddH^O with three changes of ddH^O. Freshly 
prepared staining substrate solution was added and the gel was stained at room 
temperature for about 15 minutes with gentle shaking. The gel was finally fixed in 
50ml 5% (v/v) glacial acetic acid at room temperature for 20 minutes and rinsed 
thoroughly in cffi^O before vacuum drying. 
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2.2.6.4 Protein transfer using Mini Trans-Blot Electrophoretic Transfer Cell 
(Bio-Rad) 
The process is also called "Wet Transfer". The resolving gel was equilibrated in 
chilled Bjermm and Schafer-Nielsen transfer buffer for 15-30 minutes. A piece of 
0.2^im pore-size PVDF membrane (Bio-Rad, Hercules, CA) cut to the size of the gel 
was activated in reagent grade methanol and then equilibrated in transfer buffer for 
15 minutes. A stack of Whatman® 3MM Chr Chromatography paper cut to the size 
of the gel was also soaked in the transfer buffer. The electrophoretic transfer cell was 
set up as illustrated in the instruction manual. Proteins were transferred from the gel 
to the PVDF membrane at lOOV for one hour. After the transfer, the membrane was 
ready for Western blotting. The efficiency of protein transfer was checked by 
staining the transferred gel with Coomassie Brilliant Blue R-250. 
2.2.6.5 Western blotting 
Each membrane was blocked in 15ml blocking buffer at room temperature for one 
hour. The blocking solution was changed and 20^ig of monoclonal antibody Mab 5.2 
were added. Probing of antigen was carried out at room temperature for one hour or 
at 4 � C overnight with gentle shaking. The membrane was then washed three times 
for ten minutes each in 25ml pre-chilled wash buffer. Aftenvards, 15ml blocking 
buffer was added with EIA-Grade affinity purified goat-anti-mouse IgG (H+L) 
AP conjugate (Bio-Rad, Hercules, CA). The membrane was incubated at room 
temperature with gentle shaking for one hour and it was washed again as mentioned 
before. Finally, after rinsing the membrane with 2ml AP substrate buffer, the AP 
substrate solution was added. Colour development was carried our in the dark at 
room temperature for 20 minutes and was stopped by flushing the membrane under 
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tap water for two minutes. The membrane was then air-dried and kept away from 
strong light. 
2.2.6.6 Protein content determination by Protein Assay Kit (Bio-Rad, Hercules, 
CA) 
The working dye reagent was prepared by diluting one part of the Dye Reagent 
Concentrate with four parts of ddH^O. Twenty microlitres of protein sample or 
protein standard was mixed with 1ml of the working dye reagent. The mixture was 
incubated at room temperature for 15 minutes. Bovine Serum Albumin (BSA; 
Fraction V’ Sigma, St. Louis, MO) was used as protein standard. Optical density at 
595nm ( O D 5 9 5 ) was measured either by a spectrophotometer, with the sample loaded 
into a disposable cuvette (Sarstedt), or by a microplate reader, with the samples 
loaded into framed PolySorp polystyrene Nunc-Immuno® Modules (Nunc InterMed). 
2.2.7 Enzyme Linked Immuno-Sorbent Assay (ELISA) 
2.2.7.1 ELISA 
ELISA was used to determine the titer of the anti-body raised by immunizing rabbits 
with C-hisPyMSP-l42 and N-hisPAISP-l42. C-hisPyMSP-l42 or N-hisPyMSP-U^ 
diluted in ELISA coupling buffer (O.S^ig/ml; lOO^il/well) was coated onto 96-well 
MaxiSorp polystyrene plates (NalgeNunc International) at 4 � C for 16-24 hours. The 
plates were flicker-dried and washed three times for five minutes each with 
200^il/well of blocking buffer. Saturation buffer was pipetted into the plates at 
2001/well and incubated for one hour. The plates were flicker-dried and washed three 
times for five minutes each with 200nl/well of blocking buffer and followed by 
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washing with washing buffer. Rabbit antiserum against recombinant P^MSP-Ui 
protein was serially diluted and pipetted into the plates at lOO^ywell. The plates 
were incubated at room temperature for one hour. Afterward, the plates were then 
flicker-dried and washed five time for five minutes each with 200nl/well of blocking 
buffer. EIA-grade affinity purified goat-anti-rabbit IgG (H+L) HRP-conjugate (Bio-
Rad, Hercules, CA) was diluted 2000-fold in secondary antibody buffer and pipetted 
into the wells at 100^il/well. The plates were then incubated at room temperature for 
one hour. Finally, the plates were flicker-dried and washed three times for five 
minutes each with blocking buffer and then twice for five minutes each with washing 
buffer at 200|al/well. The HRP substrate mix was added at lOO^il/well and colour 
development was performed by incubating the plates at 37°C for 20 minutes. Optical 
density at 405mn (OD405) was measured by a microplate reader (Molecular Devices 
or Bio-Rad). Blanks were included in the plates in which all antigens and antibodies 
were omitted except the respective buffers. 
2.2.7.2 Sandwich ELISA 
Mab 5.2 diluted in ELISA coupling buffer (0.5ng/ml; lOOnl/well) was coated onto 
96-well MaxiSorp polystyrene plates (Nalge Nunc International) at 4 � C for 16-24 
hours. The plates were flicker-dried and washed three times for five minutes each 
with 200^il/well of blocking buffer. The plates were flicker-dried and washed three 
times for five minutes each with 200^il/well of blocking buffer and followed by 
washing with washing buffer. Recombinant PfMSP-U: was added lOOnlMell and 
incubated for one hour at room temperature or at 4 � C overnight. Rabbit antiserum 
against recombinant PfMSP-l42 protein was diluted 128,000-fold in saturation buffer 
and pipetted into the plates at lOO^U/well. The plates were incubated at room 
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temperature for one hour. Afterward, the plates were then flicker-dried and washed 
five time for five minutes each with 200^1/well of blocking buffer. EIA-grade 
affinity purified goat-anti-rabbit IgG (H+L) HRP-conjugate (Bio-Rad, Hercules, CA) 
was diluted 2000-fold in secondary antibody buffer and pipetted into the wells at 
lOO^il/well. The plates were then incubated at room temperature for one hour. Finally, 
the plates were flicker-dried and washed three times for five minutes each with 
blocking buffer and then twice for five minutes each with washing buffer, at 
200|al/well. The HRP substrate mix was added at 100|al/well and colour development 
was performed by incubating the plates at 37�C for 20 minutes. Optical density at 
405mn (OD405) was measured by a microplate reader (Molecular Devices or Bio-
Rad). Blanks were included in the plates in which all antigens and antibodies were 
omitted except the respective buffers. 
2.2.7.3 Standardization of Response Curve in Sandwich ELISA 
Since the sandwich ELISA is intended to be used to quantify the expression level of 
recombinant P>ISP-l42 protein, Mab 5.2 immunoaffinity purified recombinant 
P>lSP-l42 was used as a standard for quantitation experiments. Serially diluted 
purified recombinant PfMSP-Ui protein was first captured by Mab 5.2 coated on 
ELISA plates. lOO i^l rabbit anti-sera diluted to 128,000-fold was then added to the 
plates to determine the amount of antigens captured as described before in the 
sandwich ELISA. The standard (PyMSP-Uj) serial dilution profile and sandwich 
ELISA is shown in figure 14. The purity of Mab 5.2 affinity chromatography 
purified recombinant PfMSP-U^ is also shown in the Figure 14. The estimated ant of 
protein in the protein amount estimation of the purified PfMSP-l42 was determined 





















































































































































































































































































































































































































































































































































































































































Materials and Methods 
2.2.7.4 Competitive ELISA 
The procedures were similar to ELISA and the only differences were the coating 
protein and samples. The non-modified PyMSP-l42 was coated on the 96-well plate. 
And a serially diluted his-tagged P>lSP-l42 sample plus a constant amount of the 
corresponding anti-sera in a final volume of 100 /i 1 was added. 
2.2.8 Immunogenicity Tests 
Two rabbits each was immunized with IMAC purified recombinant C-his/^MSP-Us 
and N-hisPyMSP-l42 protein, respectively. The first immunization was given on the 
back of the neck and it consisted of lOO^il/rabbit recombinant protein in complete 
Freund's adjuvant (Sigma, St. Louis, MO). The first booster was given two weeks 
later. The second, the third and the fourth booster were then given at 14 days 
intervals. The amount of mycobacterium in CFA was successively halved in each of 
the subsequent immunization. Serum samples were collected after each 
immunization and stored at 一 2 0 � C for characterization. 
50 
Construction of Recombinant 
N-hisPJMSP-l42 and C-hisPJMSP-hi 
CHAPTER 3 
rONSITRIJCTION OF RECOMBINANT 
N-hkAyMSP-l AND C-hisP/MSP-ld. 
3.1 Construction of C-hisP/MSP-l42 
The parent recombinant transfer vector pMbac-P>ISP-l42 containing the P/MSP-I42 
insert (FigurelS) was provided by Prof. George S. N. Hui of the Department of 
Tropical Medicine and Medical Microbiology, University of Hawaii at Manoa, 
Honolulu. Custom-made primers were ordered from GibcoBRL. A forward primer 
specific to the melittin signal peptide sequence of transfer vector pMbac (42k-F_ 
SmaIN) was designed and the sequence is as follows: 
5' tag gcc cccggg ATG AAA TTC TTA GTC AAC GTT GCC 3， 
An end clamp of six nucleotides (taggcq was introduced into the 5, position of 
the primer to facilitate docking of restriction enzyme onto the PGR product for 
digestion. A Smal site (underlined) was included following the end clamp. For 
construction of 6xHis Tag Secretory PfMSP-Ui, a reverse primer specific to the 3， 
end ofPfMSP-l42 with six histidine codons was made as follows: 
5’ TAG GAT CGT CTA G A ^ T T ^ TGG TGG TGG TGa TOG TGG TGG GAA 
Xbal his 
CTG CTGAAAATAC3' 
A contiguous hexapeptide of histidine to the 3' position of PfMSP-142 with a stop 
codon was introduced (TAA). Xbal restriction site (underlined) was introduced into 
3，end ofP£MSP-l42. PGR was performed to amplify the C-HisSp42 construct using 
the two primers mentioned above. 
51 
Construction of Recombinant 
N-hisPJMSP-l42 and C-hisPJMSP-142 
The transfer vector pBM030 was a gift from Prof. Susuma Maeda of the Department 
of Entomology, University of California, Davis (Figure 16). The PGR product of 
sp42 was digested with Smal and Xbal for cloning into pBM030/5007VcoI transfer 
vector. After the ligation of C-HisSp42 insert with compatible ends and Smal and 
Xbal digested pBMOSO/SOOA c^oI, the ligated products were electroporated into 
electrocompetent Kcoli ElectroMax DHIOB™ (GibcoBRL) cells. The overall 
strategy for construction of pBM030/C-HisSp42 is illustrated in Figure 17. 
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Figure 15. Restriction map of transfer vector pMbac (upper) and the honeybee 
melittin signal peptide sequence downstream of the polh promoter (lower) ihe 
cleavage site of the signal peptide is indicated by the arrow. PfMSP-Ui (underlined) 
was cloned into the Smal site beforehand. (Map of pMbac adopted from Lopez-
Ferber et aL, 1995) 
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Figure 16. Restriction map of transfer vector pBM030 (upper) and the Aa^ng 
S e n c e of the multiple cloning site (lower). The 严「二I site at P � s i = = 7 0 0 
absent when comparing to that in Horiuchi et al (1987) and is c o ^ r ^二 by 
restriction mapping analysis in the present study. Shaded regions r e p r e s e n t the 
flawing sequences of the viral p./；, gene required for homologous recombination. 






















































































































































































































































































































































































































































































































Construction of Recombinant 
N-hisPJMSP-hi and C-hisPJMSP-h: 
3.2 Construction of N-hisPyMSP-l42 
Custom-made primers were designed for construction of Secretoiy N-terminal 6x His 
tagged PfMSP-l42. Forward and reverse primers are as follows: 
5，C CAC CAC CAC CAC CAC CAC GCA ATA TCT GTC ACA ATG GAT AAT 
ATC3， 
5, TAG GCC CCT CTAGAT TAG GAA CTG CAG AAA ATA 3’ 
pBM030/PfMSP-l42 was used as the vector backbone for construction. 
pBM030/PfMSP-l42was first restricted by Ncol restriction enzyme and then the 5， 
protruding end was removed by Mung Bean nuclease treatment. The PfMSP-l42 
fragment was then released by Xbal cut. After GeneClean®, the vector with a blunt 
end and a sticky end was ready for ligation with the insert prepared by PCR (Figure 
18). N-terminal 6x histidines tagged p42 sequences were amplified from their pMbac 
(provided by Prof. George S. N. Hui) containing vector by PCR. The PCR amplified 
products were cut by Xbal and ligated with the pBMOSO pre-cut vector, which 
contained the signal peptide sequence. The overall strategy in construction of 
pBM030/N-HisSp42 ofFVO and 3D7 strains is as illustrated in Figure 18. 
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rHAPTER 4 
PTTRTFTCATtON WTTH IMMOBTT TZED METAL 
a f f t n t t y c h r o m a t o g r a p h y a M A C ) 
4.1 Immobilized metal affinity chromatography (IMAC) 
Immobilized metal affinity chromatography (IMAC) is a powerful technique, which 
was first used to purify proteins in 1975 (Porath et a/.，1975) using the chelating 
ligand iminodiacetic acid (IDA, Figure 19). A metal chelating group is first 
immobilized on a chromatographic medium (e.g. IDA), and a multivalent metal ion 
(usually CV+’ 风2+，Zn^^ Ca2+’ Co^^ Mg^^ etc.) is bound in a way that leaves some 
coordination sites free for selective interaction with the proteins. Typically, 5-6 
histidine residues ("tag") are added to the C- or N-terminus of a target protein using 
recombinant techniques. The tag specifically interacts with the chelated metal ions, 
thereby holding these proteins on the medium. Other components bind weakly or not 
at all. Elution of the fusion protein is usually performed by increasing the 
concentration of a competitive eluting agent, such as imidazole, or by reducing the 
pH. 
Protein with a hexa-histidine tail can bind to affinity column with metal ion chelation 
group. The poorly immunogenic hexa-histidine tail enables a recombinant protein to 
be used as antigen to generate antibody against the protein of interest without prior 
removing it. At pH 8.0, the his-tag is small, uncharged, and therefore does not 
generally affect secretion, compartmentalization, or folding of the fusion protein 
within the cell. In most cases, the 6xHis tag does not interfere with the structure or 
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function of the purified protein as demonstrated in a wide variety of proteins, 
including enzymes (Oswald et al., 1994)，transcription factors (Janknecht et ai, 
1991), and engineered antibodies (Watkins et al., 1997). As mentioned, his-tag 
labeled proteins have high affinity for the metal-chelating column surface such as 
iminodiacetic acid (IDA), therefore metal-chelating affinity chromatography is a 
very powerful tool for downstream purification. Moreover, anti-his tag antibodies 
can be used for detection of his-tag protein. 
To purify the recombinant N-hisPfMSP-l42 and C-hisP#SP-l42’ different elution 
schemes were tried. In the beginning, the optimal binding buffers (Start buffer) were 
determined by trying different pH and NaCl concentration. Start buffer for N-
hisPfMSP-l42 was 20mM Na^HPCVlM NaCl, pH 7.0 and for C-hisP>lSP-l42 was 
20mM Na2HP04/2M NaCl, pH 8.0. In this study, different washing and elution 
conditions were tried by changing pH and imidazole concentration. All buffers were 
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Figure 19: Interaction between metal ions charged chelating matrix and 6xHis 
polypeptide. A. Showing two different chelating matrix iminodiacetic acid (IDA) and 
Nitrotriacetic acid (NTA) interacting with nickel ion (Ni^ " .^ B. Schematic diagram 
showing the interaction between the matrix and 6xHis protein through the charged 
metal ion. C. Showing neighboring residue in the 6 His-tag and Ni-NTA matrix. (A 
& C adapted from Handbooks and Protocols online provided by Qiagen; 
http://www.qiagen.com/literature/hanclbooks/qxp/qxpda/1017396_HBQXP_intro.pdf) 
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4.2 Purification of N-hisPyMSP-Ui 
Nickel ion charged Chelating Sepharose Fast Flow was prepared as described in 
section 2.2.2.1. Insoluble materials in the hemolymph were removed by 
centrifugation at 13,000rpm at 4�C for 20 minutes before the sample was used for 
purification. 5 ml of infected hemolymph was dialyzed in a 3000-8000 NMWL 
dialysis tubing against 5L Start buffer at 4 � C overnight. The dialyzed hemolymph 
sample was diluted 3-fold and filtered with a 0.45nm filter, then mixed with 2.5ml 
charged chelating matrix in a 50ml Falcon tube. The mixture was gently rotated until 
fully suspended. It was then incubated at 4°C overnight with end-over-end rotation. 
The gel slurry was then packed into a 1cm x 5cm glass column (BioRad). Different 
concentrations of imidazole with Start buffer were used to determine the optimal 
imidazole condition for elimination of contaminants. 
As indicated in Figure 20 by SDS-PAGE and Western blot analysis, no target protein 
appeared in the unabsorbed fraction. After overnight binding, 20-bed volume of Start 
Buffer (SB, 20mM NaiHPOVlM NaCl, pH 7.0) was used to wash the unbound 
materials. After washing, different concentrations of imidazole were used to optimize 
the elation of the contaminants. lOmM, 20mM, 30mM, 40mM, and 50mM of 
imidazole/SB were tried. As indicated in Figure 21，lOmM, 20mM, and 30mM 
imidazole/SB were able to wash out the loosely bound contaminants. At 40mM and 
50mM imidazole/SB, several major bands together with some weaker bands were 
eluted. By Western blotting, the weaker band was determined to be our target protein. 
In order to eliminate the major contaminating bands, higher concentrations of 
imidazole/SB were tried, however, even with a fine increment of increasing 
imidazole concentration, the major contaminating bands could not be resolved from 
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the target protein. The two contaminating bands always co-eluted with the target 
protein. As such, 40mM and 50mM imidazole/SB appeared to be the best choice for 
washing buffer. 
To test if pH could affect purification, an elution buffer containing 50mM 
imidazole/SB at pH 5.5 was tried. The proteins pattern eluted showed no difference 
compared with that obtained at pH 7.0. Therefore, elution at a lower pH did not seem 
to produce any better result. In the process of optimizing purification, we found that 
lipids and lipoproteins may interfere with the process; therefore, steps were taken to 
remove lipids and lipoproteins in the sample first. To do this, a 24-hour 
centrifligation step was added to remove most of the lipids. Unfortunately, after 
centrifiigation, most of the proteins were degraded (Figure 22) and this might have 
been due to an increase of process time. In order to reduce non-specific binding and 
avoid oxidizing, Igepal, a detergent, and p-mercaptoethanol were added to facilitate 
purification. However, their addition did not give a better result. Both SDS-PAGE 
and western blot result did not show any significant difference with and without 
Igepal and P-mercaptoethanol addition. 
In other attempts to purify N-his/^SP-Uz, a number of protocols have been tried. 
None of them preformed better than the original protocol mentioned above. The 
following is a summary of these procedures. 
Method 1: 5ml frozen hemolymph was thawed and centrifliged at 15,000 rpm for 15 
minutes at 4°C. The lipids floated on the top of the centrifuge tube were removed very 
carefully by aspiration using a glass capillary pipette. The lipid free subnatant was collected 
and dialyzed against three one liter changes of buffer I (83mM Borate buffer with IM NaCl, 
5mM imidazole, 5mM P-mercaptoethanol, and 0.01% Igepal, pH 8.0) at 4�C. 2.5 ml Nickel 
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ion charged Chelating Sepharose Fast Flow was prepared as described in section 
2.2.2.1. It was then mixed with the hemolymph and rotated overnight at 4�C. The next 
day, the beads was washed 3x with 10ml volumes of cold buffer I and eluted by buffer II 
(lOOmM NaCl/200mM sodium acetate, pH 4.0). 
Method 2: This protocol was similar but with different buffers. The centrifiiged hemolymph 
was dialyzed with 4L pH 9.0 buffer containing 410g NaCl, 2ml Igepal’ P-
mercaptoethanol and 1.36g imidazole. Buffer I was 200ml BBS with 21.8g NaCl, 140^1 P-
mercaptoethanol, 0.136g imidazole and 0.4ml Igepal. BBS was a pH 8.0 buffer with 167mM 
boric acid, 134mM NaCl and 27.5mM NaOH. 2.5 ml nickel ion charged Chelating 
Sepharose Fast Flow was prepared as described in section 2.2.2.1. The beads were 
washed with 500ml BBS with 250^1 Igepal and 54.5g NaCl. It was then mixed with the 
hemolymph and rotated overnight at 4°C. The next day, the beads were washed 3x with 
10ml volumes of cold buffer I and eluted by buffer II. Buffer II was a pH 4.0 buffer 
containing 1.64gNa Acetate, ll.TgNaCl, lO^ U Igepal in 100ml ddHzO. 
Using both of the above methods we did not obtain better results. As indicated in 
Figure 23, there were still had three main bands and a number of minor bands in the 
purified samples. Because of these results, the optimal condition to purify N-
hisPyMSP-l42 was to use SOmM imidazole to wash the contaminants that bound to 
the IMAC column. 
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Marker FT 
� a ) FT Marker (Da) 
113,000 113,000 
93,000 93,000 
Most of the target protein ^ ^ ^ ^ 參 
50，300 was absorbed by IMAC ^ ^ B l y 50,300 
Q g p column 
35,500 35,500 
28,800 ^ ^ K ,；； 28,800 
21,400 ^ ^ B H 21,400 
Western Blot (Mab 5.2) SDS-PAGE 
Figure 20: The western blot and SDS-PAGE of the unbound material (Flow Through, 
FT) ofN-PyMSP-142 purification after binding with IMAC column overnight using 
start buffer 20mM Na2HP04, IM NaCl at pH 7.0. 
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Figure 21: Elutions of N-i^/MSP-Ui by increasing the concentration of imidazole. 
Lane A:20mM imidazole, Lane B: 30mM imidazole. Lane C: 40mM imidazole, Lane 
D: 50mM imidazole. Lane E: 400mM imidazole 
Western Blot by monoclonal antibody Mab 5.2 of Lane E 
(A) Purified N-his/yMSP-l42 (B) Degraded purified N-hisP/MSP-Ui 
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Figure 22: SDS-PAGE profile of N-FyMSP-l42 without the centrifugation step (A) 
and degradation of protein after the addition of a 24-hour centrifugation step (B). See 
text for details. 
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Figure 23: SDS-PAGE of N-hisPjMSP-Ui purified by Method 1 (Lane A) and 2 
(Lane B). Both methods resulted in many contaminating bands and they were not 
suitable for the purification of N-his/^SP-l42. The optimal method is presented in 
Lane S, which showed three major protein bands with a higher intensity target 
protein band. 
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4.3 Purification profile of N-hisPyMSP-l42 
N-hisPyMSP-l42 was purified by IMAC as described at 2.2.2. The unabsorbed 
fraction (FT), the first wash (Wl), the 20出 wash (W20), the 21 欢 wash (W21), the 
22nd wash (W22), the 50出 wash (W50) and four elutions (El, E2, E3, E4) were 
collected to show the purification profile. 
As indicated in the ELISA profile, the FT (0) and Wl still contained some 
immunoreactive proteins. After washing 20 bed-volumes of start buffer, all the 
unabsorbed materials were washed away； see W20 and W21 Figure 24[2]. 50mM 
imidazole/Start buffer was loaded onto the column as W21. In W22, a massive 
amount of contaminating proteins could be eluted in the presence of 50mM 
imidazole. Further washing with imidazole at this concentration was enough to 
remove most of the contaminating proteins (W50); including some of the target 
proteins. The final elution with 400mM imidazole yielded three major bands 
including our target bands (FT, El, E2). 
According to the results from ELISA and protein assay, the yield of purification 
scheme mentioned about could be calculated. Comparison of the ELISA and protein 
assay results, we can see that the percentage of our target protein at different stages 
of purification was increased from 2.5% in the flow through to 75% in the final 
elution (Figure 25). 
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Figure 24: (l)ELISA. 
The N-his/yMSP-l42 purification profile using IMAC. 
Samples were diluted into 100- and 200-fold. 
(2) SDS-PAGE 
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4.4 Purification of C-hisP/MSP-l42 
5ml frozen hemolymph was thawen and centrifliged at 15,000 rpm for 15 minutes at 4�C to 
remove insoluble materials. The supernatant was then collected and mixed with 5ml 20mM 
DTT and 5ml UF buffer (62.3g NaBr in 250ml MOCK buffer). The mixture was centr i f i iged 
at 42,000rpm for 24 hours at 4 �C. The lipids collected on the top of the centrifuge tube were 
removed by aspiration with a glass capillary pipette. The bottom 1/3 of the tube containing 
the target proteins were collected after removing the upper 2/3 phase by pipetting. The 
collected bottom fraction was dialyzed against three 5 liter changes of Start buffer (SB， 
20mM Na2HP04, 2M NaCl, pH 8.0). The dialyzed hemolymph sample was diluted 3-
fold with Start buffer and filtered with a 0.45|im filter. The sample was then mixed 
with 2.5ml charged chelating matrix in a 50ml Falcon tube. The mixture was gently 
shocked until fully resuspended. It was then rotated end-over-end at 4°C overnight. 
Afterwards, the slurry mixture was packed into a glass Econo-Column (10mm x 
10mm, BioRad). The eluent of the final pass was saved as the flow through (FT). 
The column was then washed with 20-bed volumes of Start buffer followed by a 
second round with a buffer containing 50mM imidazole in Start buffer, pH 6.0 (50-
bed volume). Absorbed materials were eluted by washing with four one-bed volumes 
of elution buffer (0.4M imidazole in Start buffer, pH 5.5). 
As indicated in Figure 26, the optimal condition for C-hisPyMSP-U^ purification was 
similar to N-hisP^ISP-U^. In the purified fraction, three bands of proteins were 
obtained. Compared to N-hisP>lSP-l42 purification, the contaminant bands were 
much more weaker. 
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Hemolymph FT Wash Elutions 
22-23 (E1-E4) 
ELISA 7.44 mg 0.39 mg 1.62 mg 3.57 mg 
Percentage of lost/yield ^ 5.24% 21.77% 47.98% 
Protein — 15.43 mg 3.9 mg 4.71 mg 
Assay 
Percentage of N-hisP>ISP- — 2.53% 41.54% 75.80% 
I42 in the sample 
The yield of N-hisP>ISP-l42 was 47.98% and there was 21.77% of target protein 
lost during the wash using 50mM imidazole. 
The 75.80% of purified N-hisPyMSP-142 could be recognized by Mab 5.2. 
Figure 25: The yield of N-hisP>lSP-l42 by IMAC purification. The data was the 
average of three batches 5-ml hemolymph purification. 
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SDS-PAGE Western Blot (Mab5.2) 
Figure 26:SDS-PAGE and Western Blot of purified C-hisF/MSP-Uz- SDS-PAGE 
showed a high intensity of the target band. Mab 5.2 was used for the western blot and 
a major band (target protein) and a very minor band were observed. 
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4.5 Purification profile of C-his/yMSP-l42 
C-hisP>ISP-l42 was purified by IMAC as described at 2.2.2. The unabsorbed 
fraction (FT), the first wash (Wl), the 20出 wash (W20), the 21 议 wash (W21)，the 
22"^ wash (W22), the 50出 wash (W50) and four elutions (El, E2, E3, E4) were 
collected to show the purification profile. 
The purification profile of C-hisP^SP-Ui was similar to the N-hisPyMSP-l42 one. 
As indicated in the ELISA profile, the FT (0) and Wl still contained target proteins. 
After washing 20 bed-volumes of start buffer, all the unabsorbed materials were 
washed away; see W20 and W21 Figure 27[2]. 50mM imidazole/Start buffer was 
loaded onto the column in W21. In W22 and 23’ a massive amount of contaminating 
proteins could be eluted in the presence of 50mM imidazole. Further washing with 
imidazole at this concentration was enough to remove most of the contaminating 
proteins (W50), including some of out target proteins (see ELISA profile also). The 
final elution with 400mM imidazole yielded three major bands including our target 
bands (42kDa). 
Base on the results from ELISA and protein assay, the yield of this purification 
scheme could be calculated. Comparison of the ELISA and protein assay results, we 
can see that the percentage of our target protein at different stages of purification was 
increased from 2.33% in the flow through to 82% in the final elution. 
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Figure 27: (1) ELISA. 
The C-his/yMSP-l42 purification profile using IMAC. 
Samples were diluted into 100- and 200-fold. 
(2) SDS-PAGE 
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“ H e m o l y m p h FT W a s h E l u t i o n s 
22-23 (E1-E4) 
ELISA 8.50 mg 0.31 mg 2.11 mg 4.96 mg 
Percentage of lost/yield — ^ ^ ^ 5 8 . 3 5 % 
• p ^ ^ ^ 13.29 mg 5.41 m g 6 . 0 4 mg ' 
PeZntageofN-hisPyMSP- ：… 2.33%— 39.00% p ： ! ^ 
I42 in the sample J • 
The yield of C-hisP^MSP-U^ was 58.35% and there was 24.82% of target protein 
lost during the wash using 50mM imidazole. 
82.12% of the purified C-hisP>lSP-l42 by IMAC purification could be recognized 
by Mab 5.2. 
Figure 28: The yield of C-hisP>ISP-l42 by IMAC purification. The data was the 
average of three batches of5-ml hemolymph purification. 
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4.6 Expression pattern of Recombinant N-hisPyMSP-Ui 
Since the material used for purification was derived form the hemolymph of BmV 
infected silkworms, a high degree of variability in yield and product degradation may 
result from batch to batch variation as well as the timing of sample collection. Hence, 
it is necessary to define which day is the most optimal time for collecting the 
hemolymph to ensure consistence in purification. To evaluate this, hemolymph was 
collected over a period of 6 days after infection. The samples were purified by IMAC 
and analyzed by SDS-PAGE. From the SDS-PAGE (Figure 29) expression of our 
target protein was observable starting at Day 4 post infection. The sample collected 
at Day 5 was the cleanest in terms of contaminating bands. Based on this study, the 
harvest of the hemolymph appears to be best at Day 5 as it is the most optimal time 
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Figure 29: Expression of N-hisP/MSP-l42 after infection. The hemolymph was 
collected starting from the first day of infection and purified by IMAC. 
Lane 5a & 6a were the hemolymph collected in Day 5 plus 4 hours and Day 6 plus 4 
hours respectively. 
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CHAPTER 5 
F U R T H E R P T m T F T C A T I O N O F P / M S P - 1 ^ U S I N G 
r w i ^ n M A T O C R A P H T C A P P R O A C H E S 
5.1 Affinity Chromatography 
The previous chapter have described the results in the purification of recombinant N-
hisPyMSP-l42 and C-hisP>ISP-l42 from hemolymph of infected silkworms by 
IMAC. Using IMAC alone we could not purify the proteins to high quality. To 
further purify these proteins, IMAC was combined with other chromatographic 
methods, such as hydrophobic interaction, sizing and ion exchange, for further 
purification. 
5.1.1 Blue Sepharose 
Blue Sepharose is a group specific adsorbent with affinity for a wide variety of 
enzymes. Some proteins interact biospecifically with the dye due to its structural 
similarity with nucleotide cofactors while others, such as albumin and interferon, 
bind in a less specific manner by electrostatic and/or hydrophobic intractions with 
the aromatic anionic ligand. Biospecifically adsorbed proteins can be eluted by low 
concentrations of the free cofactor, or increased ionic strength. Less specifically 
bound proteins require the use of much higher cofactor, or salt concentrations. The 
ligand is a dye, Cibacron^M Blue F3G-A, which is covalently attached to the highly 
cross-linked agarose gel via the triazine part of the dye molecule. 
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Since hemolymph proteins may have properties similar to serum proteins, Blue 
Sepharose 4B is a logical choice to evaluate if the medium can be used. Blue 
Sepharose 4B was prepared as described in section 2.2.2.1. The sample, which was 
purified from IMAC (N-hisP^MSP-Ui and C-hisPyMSP-Ui), was dialyzed against 
Start buffer (20mM Na^HPCU，pH 7.0) overnight at 4�C. The dialyzed sample was 
then loaded and reloaded onto the column three times. The column was washed with 
5-bed volumes of Start buffer and then 5-bed volumes each with SOOmM NaCl/SB, 
and IMNaCl/SB. Unfortunately, by SDS-PAGE and western blot analysis, the target 
proteins as well as all the contaminants were observed in the flow through fraction. 
Because of this, we have tried using another Start buffer, lOmM Tris, pH 8.0, 
however, a similar result was observed. In view of this, Blue sepharose appears to be 
an unsuitable medium for further purification. 
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5.2 Gel Filtration Chromatography 
The development of gel filtration chromatography introduced an extremely valuable 
method by which molecules may be separated from each other on the basis of their 
size. A wide range of molecular sizes can be separated by this method but for any 
particular gel matrix the range may be relatively narrow. 
The gel structure contains pores of varying diameters up to a maximum size. The test 
molecules are eluted through a column of the gel. Molecules larger than the largest 
pores in the gel are excluded from the gel structure. Smaller molecules penetrate the 
gel to a varying extent depending upon their sizes and this retards their speed of 
migration through the column. Elution, therefore, is in order of decreasing size 
(Figure 30). 
Superose 6 is a highly cross-linked 6% agarose-based medium optimised for high 
performance gel filtration. Particle size is approximately 13 i^m. The molecular 
weight range for optimal separation is 5 ,000-5x 10^  daltons. The exclusion limit for 
globular proteins is 4 x 10^ daltons. 
Samples purified from 5ml hemolymph by M A C was concentrated into 1ml and 
then was loaded onto a Superose 6 column (10cm x 30cm Pharmacia). 
Chromatography was performed in a ¥?LC system (Pharmacia). The column was 
eluted with a buffer containing 20mM Na2HP04, IM NaCl and pH7.0 at a flow rate 
of 0.5ml per minute. The elution profile was monitored by absorption at 280nm 
(OD280) (Figure 31). By SDS-PAGE and western blot analysis (Figure 31)，Superose 
6 is not a suitable medium for further purification. In SDS-PAGE, fraction 2 only 
contained very weak contaminating bands, however, as indicated, all three peaks 
contained PyMSP-142 as determined by western blotting. 
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5.3 Ion Change Chromatography 
Ion exchange chromatography was developed by D'Alelio in 1942 using synthetic 
ion exchange media based on the polystyrene resins which extended the use of ion 
exchange as an analytical tool. 
Separation in ion exchange chromatography depends upon the reversible adsorption 
of charged solute molecules to an immobilized ion exchange group of the opposite 
charge. Separation is obtained since different substances have different degrees of 
interaction with the ion exchanger due to differences in their charges and charge 
densities. These interactions can be controlled by varying conditions such as ionic 
strength and pH. The differences in charge properties of biological compounds are 
often considerable and ion exchange chromatography is capable of separating species 
with very minor differences in properties, e.g. two proteins differing by only one 
charged amino acid. 
An ion exchanger consists of an insoluble porous matrix to which charged groups are 
covalently bound. The charged groups are associated with mobile counter-ions. 
These counter-ions can be reversibly exchanged with other ions of the same charge 
without altering the matrix. It is possible to have both positively and negatively 
charged exchangers (Figure 32). Positively charged exchangers have negatively 
charged counter-ions (anions) available for exchange and thus are called anion 
exchangers. Negatively charged exchangers have positively charged counter-ions 
(cations) and are called cation exchangers. 
Ion exchange chromatography is based on the binding of charged sample molecules 
to oppositely charged groups attached to an insoluble matrix. Substances are bound 
to ion exchangers when they carry a net charge opposite to that of the ion exchanger. 
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ANION exchanger with CATION exchanger with 
exchangeable counter ions exchangeable counter 10ns 
Figure 32: Ion exchanger types 
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This binding is electrostatic and reversible. The pH value at which a biomolecule 
carries no net charge is called the isoelectric point (pi). When exposed to a pH below 
its pi, the biomolecule will carry a positive net charge and will bind to a cation 
exchanger. At pH's above its pi, the biomolecule will carry a negative net charge and 
will bind to an anion exchanger. In this study, the theoretical pi of recombinant 
P^SP- l42 is calculated to be 5.7. 
In our investigation, the following ion-exchange media were tried: CM Sepharose 
Fast Flow, a weak cation exchanger (Amersham Biosciences), Q Sepharose Fast 
Flow, a strong anion exchanger (Amersham Biosciences), and DEAE Sepharose Fast 
Flow, a weak anion exchanger (Amersham Biosciences) and ANX Sepharose Fast 
Flow ’ a weak anion exchanger (Amersham Biosciences). 
All buffers and samples were filtered by 0.45nm pore-size membrane filtration 
before used. Samples from IMAC (Figure 33) were dialyzed at 4 � C overnight with 
Start buffer and ion exchange chromatography was performed immediately. 
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Figure 33-.Purified C-hisF/MSP-Ui and N-hisP/MSP-Ui 
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5.3.1 CM Sepharose Fast Flow 
CM Sepharose Fast Flow is based on a robust 6% highly cross-linked beaded agarose 
matrix containing the weakly negative-charged -O-CHzCOO. group. The column 
volume used was 1ml with a dimension of 0.7 x 2.5cm. 
As this matrix is a weak cation exchanger, the recombinant P/MSP-I42 should bind 
to it at a pH lower than 5.7. Therefore, the pH of the Start buffer (SB, 20mM 
Na2HP04) was adjusted to 5.0. The sample, which was purified from IMAC (N-
hisPyMSP-l42 and C-hisP^lSP-Ui), was loaded and reloaded three times. The 
column was washed with 5-bed volumes of Start buffer and then eluted with 5-bed 
volumes each with lOOmM NaCl/SB, 200mM NaCl/SB, 400mM NaCl/SB, 600mM 
NaCl/SB, SOOmM NaCl/SB, and finally IMNaCl/SB. The first three fractions were 
collected after each elution and analyzed by SDS-PAGE. No band was observed after 
silver staining for both sample containing N-hisP>ISP-l42 and C-hisP>lSP-l42. 
Based on this result, CM Sepharose Fast Flow probably bound the target protein 
tightly and could not be eluted even at a salt concentration of IM. Therefore, we 
concluded that it is not a suitable medium for further purificaiton. 
5.3.2 Q Sepharose Fast Flow 
Q Sepharose Fast Flow is a strong anion exchanger based on a robust 6% cross-
linked beaded agarose matrix. The column volume used in our study was 1ml with a 
dimension of 0.7 x 2.5cm. The charged group on the exchanger is ->^(^3)3 . 
Since Q Sepharose Fast Flow is a strong anion exchanger, the recombinant P/MSP-
I42 should bind to the matrix at a pH above 5.7. Two different pH Start buffers (SB, 
20mM Na2HP04) were tried; pH 7.0 (SBl) and pH 8.0 (SB2). The sample, which 
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was purified from 5ml hemolymph by IMAC (N-hisP/MSP-U^ and C-hisPyMSP-U^), 
was loaded and reloaded on the column three times. The column was then washed 
with 5-bed volumes Start buffer 1 and then 5-bed volumes each with lOOmM 
NaCl/SBl，200mM NaCl/SBl, 400mM NaCl/SBl, 600mM NaCl/SBl, 800mM 
NaCl/SBl, and finally IM NaCl/SBl. For SB2, the procedures and the salt 
concentration used were the same as SBl. The first three fractions of each step 
elution were collected and analyzed by SDS-PAGE. However, no band was observed 
in the gel after silver staining in both the N-hisPfMSP-U^ and C-hisP^MSP-U. 
samples. According to the above result, Q Sepharose Fast Flow was not a suitable 
medium for further purifying the recombinant proteins as the target protein was 
unaccountably lost after application. 
5.3.3 DEAE Sepharose Fast Flow 
DEAE Sepharose Fast Flow is a weak anion exchanger based on a robust 6% highly 
cross-linked beaded agarose matrix. The column volume used was 1ml with a 
dimension of 0.7 x 2.5cm. The charged group on the anion exchanger is -
N"(C2H5)2H，a weakly positive-charged structure. 
As DEAE Sepharose Fast Flow is a weak anion exchanger, the recombinant P/MSP-
142 should bind to the matrix at a pH higher than 5.7. Therefore, the pH of the Start 
buffer (SB, 20mM Na.HPO^) used was 7.0. The samples, which were purified from 
5ml hemolymph by IMAC (N-hisP_/MSP山2 and C-hisPyMSP-l.), were loaded and 
reloaded onto the column three times. The column was washed with 5-bed volumes 
of Start buffer 1 and then 5-bed volumes each of lOOmMNaCl/SB, 200mMNaCl/SB, 
400mM NaCl/SB, 600mM NaCl/SB, 800mM NaCl/SB, and finally IM NaCl/SB. 
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The first three fractions of each elution step were collected and analyzed by SDS-
PAGE. The flow through fraction showed partial binding of the target protein (Figure 
34) and subsequent elution at increasing salt concentration did not separate the three 
main bands of the sample (Figure 35). In view of these results, a higher pH Start 
buffer (pH 8.0) was used. The procedures were repeated as before except using a pH 
8.0 buffer. However, no band was observed in the collected fractions after sliver 
staining. 
According to the above results, DEAE Sepharose Fast Flow again did not appear to 
be a suitable medium for further purification of the recombinant N-hisP^MSP-Ui and 
C-his/yMSP-l42 proteins. 
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Figure 34: Partial absorption of N-尸/MSP-I42 using DEAE-Sepharose 
FT (absorbed by 20mM Na2HP04, pH 7.0，SB) 
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5.3.4 ANX Sepharose Fast Flow 
ANX Sepharose Fast Flow is a weakly positively charged matrix based on a robust 
4% highly cross-linked agarose bead. The column volume used was 1ml with a 
dimension of 0.7 x 2.5cm. The charged group of this exchanger is —>r(C2H5)2H. 
ANX Sepharose Fast Flow is a weak anion exchanger so the recombinant P仰S P - I 4 2 
should bind to the matrix at a pH above 5.7. Two different pH Start buffers (SB, 
20mM Na2HP04) were tried, pH 7.0 (SBl) and pH 8.0 (SB2). The samples purified 
from IMAC (N-hisP>lSP-l42 and C-hisiyMSP-142), was loaded and reloaded three 
times onto the column. The column was washed with 5-bed volumes of Start buffer 1 
and then 5-bed volumes each with lOmM NaCl/SBl, 20mM NaCl/SBl, 40mM 
NaCl/SBl, 60mM NaCl/SBl, 80mM NaCl/SBl, and finally lOOmM NaCl/SBl. For 
SB2, the procedures and the salt c o n c e n t r a t i o n s need were the same. The first three 
fractions were collected after each elution and analyzed by SDS-PAGE. From the 
results, both SBl and SB2 showed a complete absorption of the target proteins. 
However, different NaCl concentrations could not separate the target band from the 
contaminants (Figure 35). Therefore, a lower pH Start buffer (pH 6.0) was tried. 
Unfortunately, the results were similar to those of DEAE Sepharose Fast Flow 
separation. Only partial binding of the target protein occurred and while most of 
them escaped in the flow through. 
According to the above results, ANX Sepharose Fast Flow did not appear to be a 
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Figure 35: Unsuccessful purification by ion-exchange chromatography. Three bands 
could not be separated by increasing NaCl concentration. Lane A was N-hisP/MSP-
I42 purified by DEAE-Sepharose, Lane B was N-hisF/MSP-Ui purified by ANX-
Sepharose. Under various elution scheme, the results remained unchange as showed 
above. (SDS-PAGE was over-stained) 
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5.4 Conclusion 
The use of a number of chromatographic media to further purify both N- and C-
PyMSP-l42 appears to have no improvement from IMAC. However, these results still 
gave us information about the two contaminating bands found in our samples. After 
adsorption with a wide range of chromatographic media, the two contaminating 
bands are still associated with our target protein. In this respect, it is likely that they 
may share similar properties with our target protein. In the course of our study, we 
found that the purified products after IMAC could all be detected by Mab 5.2 during 
western blot. The nature of these products will be investigated in Chapter 6. 
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Mab 5.2 is a monoclonal antibody that can specifically interact with a disulphide-
dependent c o n f o r m a t i o n a l epitope on the EGF-like domain of thecarboxyl terminal 
19kd fragment of the native P>1SP-1 protein. In our purification study with IMAC, 
only the larger contaminating band detected by Mab 5.2 in western blot assay. This 
indicates that while the smaller 35kDa band was invisible only the larger band 
contains the d i su lph ide -bond c o n f o r m a t i o n a l epitope and it was probably generated 
from our target protein. By this rationale, this band could be an aggregate of the 
target protein, and IMAC as well as other chromatographic methods could not be 
used to disaggregate it. In this Chapter, we attempted to use immuno-affinity 
chromatography together with IMAC to investigate the identity of the smaller 
contaminating protein band. As indicated by SDS-PAGE, the size of this 
contaminating band is 35kDa which may be a 33kDa cleavage product from the 
target protein because this fragment does not contain the 19kd EGF-like domain, it 
therefore cannot be detected by Mab 5.2. 
In our experiment, we first purified N-P^MSP-U. and C-P^ISP-U. from the 
hemolymph by IMAC as described in section 2.2.2 and 2.2.3.. The procedures used 
were the same for both for N- and C-PyMSP-U^. The M A C purified products were 
then dialyzed against 5L PBS/IM NaCl pH7.0 (Start buffer, SB) and the sample was 
then loaded onto a 2ml Mab 5.2 immuno-affinity column. The unabsorbed material 
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(FT) was collected and the column was washed with 5-bed volumes of PBS/IM 
NaCl/0.1%NP-40 and the 5-bed volumes of PBS/IM NaCl pH 7.0. Finally, the 
absorbed materials were eluted by washing with four one-bed volumes of elution 
buffer (O.IM glycine, pH2.7). 
The absorbed samples were analyzed by SDS-PAGE and western blot. The result 
indicated that immuno-afFinity chromagraphy could be used successfully to purify 
the target protein. By using Mab 5.2 and anti-33k specific polysemm to probe the 
western blot, we can compare the results between IMAC alone and IMAC with 
immuno-affinity chromatography. 
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Figure 36: Western Blot probed by anti-MSP-hs polysemm on N- and C-hi&P/MSP-
I42 proteins purified by (1) IMAC and (2) combined IMAC and immunoaffinity 
chromatography. 
Lane A: N-hisP/MSP-Ui 
Lane B: C-his/yMSP-142 
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Figure 37: Western Blot probed with Mab 5.2 on. N- and C-hisF/MSP-142 protein 
purified by combined IMAC and immunoaffmity chromatography 
} 
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In the western blot probed by Mab 5.2, both the N- and C-hisPyMSP-1. purified 
proteins gave the same results (Figure 37). The aggregated protein band and the 
target protein band could be visualized only because Mab 5.2 can specifically 
recognize the M S P - l . fragment but not the MSP-I33 one, i.e. the 35kDa 
contaminating band. By using an頻SP- I 3 3 specific semm to probe the same 
western blot (Figure 36), a different result was observed. The �35kDa band was 
visible in the N-hisPyMSP-U. sample but not the C-hisP^ISP-U. sample. In the 
case ofN-hisPyMSP-U. both the target protein and the 33k contaminating band 
could be purified by IMAC as both fragments would contain the his-tag group. As 
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indicated in the c o r r e s p o n d i n g SDS-PAGE and western blot (anti-33k) strong signal 
was observed in both bands (Figure 36[1]). However, by Mab 5.2 immuno-affinity 
chromatography, the degraded 33k protein band would not be absorbed as it would 
have no affinity for the Mab. In the SDS-PAGE and western blot probed with 33k 
specific serum, the intensity of this contaminating band was significantly reduced 
(Figure 36[2]). The trace amount of33kDa present after Mab 5.2 immuno-affinity 
chromatography may be due to subsequent degradation of the 42kDa fragment. As 
the three protein bands observed after IMAC were all generated from the target 
MSP-142 protein, they would all could act as against the malaria parasite. In the 
following Chapter, we have used the IMAC purified both N- and C-hisP>ISP-l42 to 
characterize their immunogenicity properties. 
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CHAPTER 7 
CHARACTERISTIC OF 
N-hisP/MS?-l.. & C-hisP/MSP-L, 
7.1 Immunogenicity of C- and N-PyMSP-142 
The immunogenicity of the C- and N-PyMSP-l42 was examined by immunizing New 
Zealand white rabbits with the protein (100 n g) in the presence of complete Freund's 
adjuvant. Rabbit sera were collected at day 1’ 14，28 and 42 (denoted as the 
secondary, tertiary and quaternary bleed) and the anti-PyMSP-l42 antibody titers of 
the sera were used as a measure of the immunogenicity of the recombinant P^MSP-
I42 protein by ELISA. Two rabbits were used for each PyMSP-Ui study. A high 
antibody titer against both PyMSPl-42 proteins was observed after immunization 
(Figure 38 & 39). This indicates that the recombinant N- and C-P^MSP-Ui proteins 
were highly immunogenic. A steady increase in antibody titers could be observed in 
the immunized rabbits over the period of immunization. The results clearly 
demonstrated that both the recombinant P^SP-l42 proteins could induce a high 
antibody response soon after immunization. 
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Figure 38: End-point titers of anti-C-hisP/MSP-142 antisera. 100/zg protein per dose 
in Freund's adjuvant was used. The antisera titers were assayed at the indicated time 
point. The end-point titer was set at OD405 of 0.2. 
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Figure 39a: End-point titers of anti-N-his?/MSP-l42 antisera. 100 fi g protein per 
dose in Freund's adjuvant was used. The antisera titers were assayed at the indicated 
time point. The end-point titer was set at OD405 of 0.2. 
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7.2 Competitive ELISA 
A competitive ELISA was performed to evaluate the reactivity of the fourth-bleed 
anti-sera against non-modified P/MSP-I42 vs the modified ones. The non-modified 
pyMSP-l42 was coated on a 96-well plate. A serial diluted his-tagged P_/MSP-l42 
sample and a constant amount of anti-serum of the corresponding his-tagged proteins 
were mixed and added into the wells (100/zl). The result (Figure 40) shows that 
there was competition between the non-modified PyMSP-l42 and the his-tagged 
PyMSP-l42. This indicates that the his-tagged proteins share similar conformation as 
the native one and the anti-sera raised against the his-tagged proteins could recognize 
both forms ofMSP-l42with similar efficiency. Since the non-modified P^ISP-W 
has already been proven to behave similarity as the native P^MSP-l protein (Pang, 
2000), Therefore, this preliminary result indicates that antisera raised against the his-
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Figure 40: Competitive ELISA. 5|ig/well non-modified MSP-I42 was coat on the 
ELISA plate. Respective rabbit anti-hisMSP-142 polysera used were the last bleed 
samples and diluted according to their IC50, N-his/yMSP-Ui-rabbit II (1/128,000), 





The aim of this study is to produce a vaccine base on the 42kDa carboxyl-terminal 
processing fragment o^ Plasmodium falciparum Merozoite surface protein (P^MSP-
I42) using the Bomhyx mori Nuclear Polyhedrosis Virus (BmNPV) expression system 
in silkworm. Chang et al” (1992) have successfully expressed P /MSP -I42 
recombinant protein in AcNPV infected Sf9 insect cell culture. There is strong 
evidence indicating that the recombinant P^MSP-Uj protein expressed in baculovinis 
could be used as an immunogen to stimulate protection when monkeys were 
challenged with live parasite in vivo (Chang et al., 1996; Stowers et al, 2001). 
However, difficulties in making the antigen reproducibly and the cost of large-scale 
production in cell culture have stymied further development. In order to produce a 
baculovirus-expressed form ofPfMSP-l42 in large scale with lower operating cost, 
we choose to use BmNPV instead of AcNPV in the present study. The advantage of 
using BmNPV is because silkworms, the natural host for this virus, can be used as an 
economical bioreactor to produce the recombinant protein in high yield. 
High level of expression of recombinant PfMSP-l42 has been achieved in our 
laboratory (Pang, 2000). In cell culture, a yield of 5.28ng/ 6XIO5 cells could be 
obtained in four days. In silkworm, the level of expression reached 378.86^g/ ml 
hemolymph after seven days of infection. In spite of these encouraging results, we 
could not find a good scheme to purify the recombinant protein using conventional 
chromatographic techniques. Therefore, a hexa-histidine tagged PfMSP-142 fusion 
protein was constructed (Chan, 2002). An isolate, 3D7, of Plasmodium falcipanm 
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was used for production of the recombinant PfMSP-Us protein. The constructs were 
all designed to secret the target protein using a honeybee melititin signal peptide and 
containing a hexa-histidine tail at either the C- or N-terminus. These strategies were 
used to stabilize expression and facilitate the purification of the recombinant protein 
by using IMAC. 
Since large-scale production of recombinant C- and N-hisPyMSP-l42 protein is our 
final goal, in vitro expression in cell culture may not be economical as the medium 
used is expensive and the yield is low (approximately 7mg/L). Moreover, 
optimization of downstream process, such as that described by Stower {et al. 2001)， 
may also reduce the yield and increase cost significantly. In contrast, the natural host 
of BmNPV, the silkworm larva, is readily available in large quantity in eastern and 
southern China. As the rearing of silkworms is well established and the cost is low, it 
is an attractive alternative to produce recombinant baculovims proteins commercially. 
Hence, using the silkworm as a bioreactor to express C- and N-hisP>lSP-l42 protein 
appears to be a cost-effective way in scaling up the production of a vaccine for 
clinical trial. 
In our laboratory, we have used immunoaffinity chromatography with monoclonal 
antibody Mab 5.2 coupled to Sepharose 4B to successfully purified the PfiA^'^-Ui 
protein form BmN infected silkworm hemolymph (Pang 2000). However, as the final 
goal is to make a recombinant vaccine for human clinical trial in compliance with 
safety and regulatory requirements of government agencies such as the U.S. Food 
and Drug Administration (FDA), the use of murine monoclonal antibody for 
immuno-affinity chromatography is undesirable as we have to prove that no 
immunoglobulin would leach from the matrix during purification (Chang, 1994). In 
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order to avoid the complex issue facing immunoaffinity chromatography, we have 
used immobilized metal affinity chromatography (MAC) purify the N- and C-
hisP>lSP-l42 in this study. Since the affinity group recognized by this type of 
chromatography is a hexa-histidine sequence, vectors were designed to contain a 
fusion protein of P^SP-l42 with a hexa-histidine tail at either the C- or the N-
terminal of the Sp42 sequence. 
Unfortunately, we were not able to establish an effective purification scheme using 
IMAC alone. Two major contaminating protein bands were still present after IMAC 
purification. Various conditions were evaluated to optimize the purification in a one 
step IMAC procedure. These included varying pH and imidazole concentration, 
detergent and /3-mercaptoethanol addition. The increase of imidazole concentration 
and decrease in pH were probably effective in removing non-specific interacting 
contaminants from the gel matrix. After a number of trials, an optimized condition 
was established. For N-hisP>ISP-l42, 20mM Na2HP04 with IM NaCl at pH 7.0 was 
used as the start buffer; 50mM imidazole at pH 7.0 was used as the washing buffer 
and 400mM imidazole at pH 7,0 was used as elution buffer. For N-hisP^MSP-Ui 
using different pH did not show any obvious improvement in purification, hence one 
pH was used consistently. However, by changing pH alone or increasing imidazole 
concentration were not effective in removing coontaminants from C-hisP^ISP-Ui. 
Therefore, we combined the two schemes together and better results were obtained. 
In this case, buffers with stepwise decrease in pH was used. 20mM Na^HPO* with 
2M NaCl at pH 8.0 was used as start buffer; 50mM imidazole at pH 6.0 was used as 
the washing buffer and 400mM imidazole at pH 5.5 was used as the elution buffer. 
Because of the compromise between high purity and the loss of target protein, 50mM 
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seems to be the most suitable concentration of imidazole to use as the washing buffer. 
The use of 400mM imidazole was apparently effective in striping out the his-tagged 
protein in the final step. This presumably can concentrate all the protein of interest in 
one or two column volumes. 
For different batches of infection, various amounts of target protein were produced 
by the silkworms because the day in collecting hemolymph was not optimized. If the 
hemolymph was harvested too early, the amount of protein obtained was low, but if 
it was not harvested in time, over-infection may result and the larva will die resulting 
in melanization of the hemolymph and product proteolysis. Under such condition, 
proteins and lipids, including the product of interest, will turn into a dark black gluey 
gum which makes recovery impossible. In an attempt to optimize the time of 
infection and collection of hemolymph, hemolymph was collected everyday after 
infection until the 6山 day. After IMAC purification, the hemolymph of Day Five 
showed the best result. Samples collected on this day have the faintest contaminating 
bands but apparently thicker target band. Therefore, the fifth day after infection is the 
most suitable day to collect hemolymph. 
The yield of the present purification protocol for both C- and N-hisPyMSP-l42 was 
quite low. For both recombinant proteins, ELISA showed that there was target 
protein in the through flow (FT) and the wash with 50mM imidazole. A large volume 
of Ni-chelating gel was not preferred because the recombinant proteins degraded 
severely during the time-consuming concentration processes. Also, the total amount 
of target protein was not the same in different batches of the hemolymph, therefore, 
after different trials; a 5 ml gel was the most suitable volume to use. 
The major loss of product was in the washing procedure using 50mM imidazole. 
110 
Discussion 
However, this loss was unavoidable. As mentioned before, using a 50mM imidazole 
was a compromise between avoiding loss and achieving purity. There were more 
minor bands in the eluted materials when using a lower imidazole concentration 
washing buffer. Although after using 50mM imidazole washing buffer, there were 
still two contaminating bands. This appeared to be the best condition for using IMAC 
purification. 
Since using MAC purification alone was not sufficient to purify the his-tagged 
recombinant proteins. A combination with other chromatography was used to further 
purify the materials isolated by IMAC. Affinity chromatography (Blue Sepharose), 
size-exclusion chromatography [Seperose 6 (FPLC)]，ion-exchange chromatography 
(CM Sepharose, Q Sepharose, DEAE Sepharose and ANX Sepharose) were used for 
further purification. However, none of them could further purify the materials 
isolated from IMAC. In this system, the target protein could either not be eluted or 
only eluted along with contaminating proteins. 
Although we could not further purify the IMAC products using other type of 
chromatography, the results gave us a clue that the three different proteins share 
similar chromatographic properties and therefore could not be isolated with these 
chromatography methods. Moreover, we noticed that the monoclonal antibody Mab 
5.2 could bind to the largest c o n t a m i n a t i n g band in western blot. Mab 5.2 is a 
conformational specific monoclonal antibody, which targets to the S-S bonding in 
the EGF-like domains of native Sp42. Therefore, we suspected that those two 
contaminating bands were the aggregation and degradation products of the target 
protein. The sizes of two bands are approximately lOOkDa and 35kDa. Therefore, we 
used another antibody, which was against the MSP-I33 protein for the western blot 
111 
Discussion 
after IMAC purification. The result in N-hisPyMSP-l42, showed that there were high-
intensity signals of both the target protein and the � 3 5 k : protein. But for C-
hisPyMSP-l42, there was strong signal for target protein but very weak signal for the 
� 3 5 k : protein. Figure 41 explained how these results could be accountable by 
hypothesizing that the � 3 5 k contaminating band was a 33kd cleavage fragment of 
the his-tagged recombinant protein. To confirm this, the IMAC purified materials 
were loaded onto a Mab 5.2-coupled immunoaffinity chromatography. After 
purification, both N- and C-hisP>lSP-l42 showed the same results, i.e., the target 
protein showed a strong signal but the � 3 5 k contaminating protein very weak signal 
in the western blot using anti-MSP-hs- These results lead to the conclusion that the 
three bands observed in SDS-PAGE after IMAC purification were 1) the target 
protein and 2) an aggregation of target protein and 3) a 33kDa degraded fragment of 
the target protein. From the results, C-hisPfMSP-142 showed a better purity than N-
hisPfMSP-142 because most of the 33kDa degraded fragment of C-hisPfMSP-142 
cannot be absorbed by IMAC. And the different amount of aggregation protein may 
be due to the recombinant protein with N-terminal his-tagged affects the protein 
folding that cause more aggregation. 
As all bands were from P>ISP-l42, it is unlikely that they will affect the property of 
the IMAC purified his-tagged P^SP-l42 as a vaccine candidate. 
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Figure 41: Scheme to explain the chromatographic behavior of PJMS^-Ui. After 
degradation, only N-his/^^MSP-hs and C-hisPyMSP-li9 could bind to the gel matrix. 
The purified MAC product, N-hisF/MSP-Ui, therefore contained the F/MSP-I33, 
which gave a strong signal in western blot with anit-MSP-133 antibody, whereas 
C-his/yMSP-l42 should give no signal. 
Discussion 
In the previous study in our laboratory (Pang, 2000), BmNPV-expressed 
recombinant PyMSP-l42 protein has been proven to be biologically and 
immunologically active. By a competitive inhibition ELISA, the recombinant 
P/MSP-I42 protein was shown to behave similarly as the native P/MSP-1 protein. 
The recombinant protein was also highly immunogenic and was able to induce 
extremely high anti-P^MSP-Ui titers. Most importantly, the antisera raised against 
PyMSP-l42 were demonstrated to be effective in inhibiting parasite proliferation in an 
in vitro experiment. Take together, these results strongly suggest the effectiveness of 
the recombinant PyMSP-Ui protein as anti-erythrocytic malaria vaccine candidate. 
In the present study, the immunogenitcity of his-tagged recombinant P/MSP-Uz 
proteins was examined in a rabbit immunization experiment. The antibody titer 
obtained was lower compared with the immunization results using the non-his-
tagged recombinant P>lSP-l42 (End-point titers > 1/4,000,000). This might have 
been due to shorter duration between each booster. In the previous study, the first 
booster was given two months later and the second and the third boosters were also 
given at 14 days intervals. But in this study, the first boosters were given two weeks 
after immunization. As the immunization period was comparatively short, it might 
cause the relatively lower titer observed. 
In the present study, competitive ELISA was preformed and showed that the antisera 
raised by hexa-histidine tailed P^MSP-Ui recognized the cross-reacted with epitopes 
between non-modified P/MSP-I42 and his-tagged PyMSP-l42. This preliminary result 




In conclusion, we have demonstrated that the BmNPV expressed recombinant C- and 
N-his/^SP-l42 proteins are immunogenically active and antisera against these 
proteins can cross-react with the native /yMSP-l42 protein. Moreover, these 
recombinant proteins have an advantage over the unmodified one because their hexa-
histidine tail could be used to facilitate IMAC purification. The high level expression 
of recombinant protein in silkworm and its low operating cost in production and 
purification make the technique attractive in the scale up production of his-tagged 
MSP-142 for vaccine studies. 
Future Prospects 
We have partially purified both the C- and N-hisPyMSP-l42 in this study. In order to 
develop these proteins into a malaria vaccine, the most important experiment in the 
future is to demonstrate the similarities between the his-tagged and native PyMSP-142. 
Results in competitive ELISA and parasite inhibit assays will be most important. 
Another important point to consider in the future is to increase expression level and 
to optimize large-scale purification. Expression level of recombinant proteins can be 
further enhanced by optimizing the use of the polh promoter. Maeda (1994) has 
noticed that the expression level of a foreign gene under the controlled of polh 
promoter could drop to only 0.1-10% of that of the original polyhedrin gene. 
Transfer vectors carrying different length of sequences between the polh promoter 
and the structural gene can be designed to optimize spacing between the promoter 
and ATG start signal to improve expression level of the recombinant proteins. 
The main objective of our research is to establish a reproducible scale-up process for 
making sufficient amount his-tagged P>lSP-l42 antigen to carry out preclinial and 
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clinical trials. Base on previous studies using similar immunogens (Chang et al., 
1992； 1996; Hui et al., 1993)，we are confident that BmNPV-expressed his-tagged 
recombinant proteins can be used as an anti-malaria vaccine. This is our goal and we 
hope that a low-cost and reproducible malaria vaccine could be developed to counter 
this life-threatening disease around the world; particularly in Africa, India, South 
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